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DNA is constantly exposed to oxidants which can lead to nucleobase
damage. Chromium is of particular interest as a DNA oxidant because of its abundance in
the environment and the ease with which it can be taken into a cell. Chromate, Cr(VI),
ions are taken up by a cell through relatively non-selective anion channels which
normally regulate uptake of phosphate and sulfate ions. Once in the cell, chromate ions
are reduced by intracellular reductants such as ascorbate and glutathione to Cr(III).
Highly reactive Cr(V) and Cr(IV) species are created during this transition which are able
to directly oxidize DNA, particularly guanine residues due to their low reduction potential
relative to the other three bases, adenine, thymine, and cytosine. 7,8-dihydro-8-oxo-2’deoxyguanosine (8-oxoG) has previously been viewed as the primary marker of oxidative
stress but the reduction potential of 8-oxoG is even lower than that of the parent guanine
residue making it a prime target for further oxidative events. Spiroiminodihydantoin (Sp)
is one product of these further oxidative events.
The NEIL1 base excision repair (BER) glycosylase has been shown to
recognize and cleave the oxidative DNA lesion Sp. NEIL1 belongs to a family of three
mammalian DNA glycosylases Neil1, Neil2, and Neil3. NEIL1 and NEIL2 are both able
to recognize and cleave the oxidative lesion Sp in single stranded DNA in vitro. In
duplex DNA, only NEIL1 is able to recognize and cleave the Sp lesion.
A Neil1 -/- mouse model was recently developed and displayed a range of
metabolic disorders that could be linked to oxidative DNA damage. These altered
phenotypes included obesity, fatty liver, kidney vacuolization, hyperleptinemia,
hyperinsulinemia, and increased mitochondrial DNA damage and deletions. Using
kidney epithelial cells from the Neil1 -/- mouse model, we have shown that a NEIL1
glycosylase deficiency alters toxicity, cell cycle arrest and apoptosis patterns following
exposure to chromate.
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CHAPTER 1
Introduction

1.1

Chromium – An Occupational and Environmental Health Hazard
Hexavalent chromium – Cr(VI) - is a well established human carcinogen. The

first evidence showing that hexavalent chromium may be a carcinogen was a high
incidence of nasal tumors reported in the late 19th century in chrome pigment workers in
Scotland.1 Cr(VI) has also been shown to cause lung cancer. In the 20th century chromate
workers in Germany, the United Kingdom, and the United States showed an increased
risk for the development of lung cancer.2-5 Industries in which workers are still exposed
to Cr(VI) today include chrome plating, stainless steel welding, leather tanning, and
chrome pigment and dye production.6 Occupational hazards of hexavalent chromium are
made clear by the enhanced incidence of cancer due to workplace exposure but
environmental exposure from years of industrial dumping of chrome waste is also a major
factor to be considered in the overall risk to human health posed by Cr(VI).
Chromium exists at an average level of 100 mg/kg in the earth’s crust. The
majority of that chromium exists in the trivalent – Cr(III) – form.7 What little Cr(VI) that
is present exists mainly as chromate (CrO42-) and is much more mobile than Cr(III)
compounds due to its significantly higher solubility.7 Industrial use of chromate
chemicals that contributes to environmental contamination includes its use in cooling
towers to prevent rust accumulation, waste from the manufacture and use of chromate
compounds, and the mist of chromic acid produced in the chrome-plating industry.8 This
chromate waste can travel over significant distances if introduced into a water source.
Some of the chromate may be reduced to Cr(III), most of which will precipitate as
Cr(OH)3-3H2O but the portion that remains in the hexavalent form will be carried
downstream.7,9 People that work with chromate compounds and those that encounter
chromate compounds in the environment run a higher risk of developing cancer than the
general population. The mode of action for the carcinogenicity observed with chromate
needs to be more clearly understood in order to reduce the risks associated with human
interaction with chromate compounds.
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Chromium, especially hexavalent chromium, is of great interest not only because
of its toxic effects on humans but also because of the high risk of exposure to hexavalent
chromium that still exists for the general public. In 1992 the drinking water standard for
total chromium was lowered to 0.1 ppm due to the emergence of new information about
amounts of chromium being released into the environment.10 Between the years 1987 and
1993, there were 2,876,055 pounds of chromium released into bodies of water in the
United States and 196,880,624 pounds released on land. There are currently four
locations in Montana alone that are active superfund sites containing chromium (Table
1.1).10 The contamination stems from the mining, smelting, and wood treatment
industries. There are 719 superfund sites nationwide with chromium listed as at least one
of the contaminants present.11 Not only is the Environmental Protection Agency still
concerned about chromium exposure, so too is the Occupational Safety and Health
Administration (OSHA). In February of 2006, OSHA settled on a new standard for
occupational exposure to hexavalent chromium. The standard was lowered from 52 to 5
µg/m3 of air as an 8 hour time-weighted average for hexavalent chromium.12

Table 1.1 – Active superfund sites in Montana containing chromium.10

1.2

City

Site Name

Date of Listing

Anaconda

Anaconda Co. Smelter

Sept. 8, 1983

Butte

Montana Pole and Treating

July 22, 1987

Butte

Silver Bow Creek/Butte Area

Sept. 8, 1983

Libby

Libby Ground Water Contamination

Sept. 8, 1983

Chromium – Oxidative DNA Damage
There are a several theories that have been proposed to explain the genotoxicity of

chromium. These include the formation of DNA adducts, single strand breaks, DNA-
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protein crosslinks, and oxidized nucleobases.13 All of these theories concerning the
genotoxicity of chromium recognize Cr(VI) and not Cr(III) as the genotoxic chromium
species. This is because Cr(VI) ions, unlike Cr(III) ions, are taken up by the cell through
relatively non-selective anion channels14 which normally regulate the uptake of phosphate
and sulfate ions required for the synthesis of proteins and DNA. Cr(III) ions are able to
cross the cell membrane but rely solely on diffusion and are therefore taken up
approximately three orders of magnitude more slowly than Cr(VI) ions.15 Chromate,
phosphate and sulfate ions are all of a similar size and share the same charge and
tetrahedral geometry (Figure 1.1).1 Once in the cell, Cr(VI) is quickly reduced by a
variety of intracellular reductants including ascorbic acid and reduced thiols such as
cysteine and glutathione. Ascorbic acid is the most kinetically favored of these reductants
and is therefore generally regarded as the major intracellular reductant of Cr(VI).16 The
rapid reduction of Cr(VI) to Cr(V), Cr(IV), and finally to Cr(III) creates a concentration
gradient across the cell membrane that favors the continual uptake of Cr(VI) from the
extracellular matrix.

O
HO

O

P

O

O

O

Cr

O
O

Figure 1.1 – Phosphate and chromate ions at physiological pH.

Cr(VI) can gain access to the cell but it is not Cr(VI) that causes damage to
nucleic acids. The reduced forms of Cr(VI) – Cr(V), Cr(IV), and Cr(III) are the species
which interact with DNA.17 Cr(V) species have been shown to directly oxidize the
nucleobases.18 The highly reactive Cr(V) species can abstract an electron from the
conjugated ring system of DNA.19 Guanine residues are preferentially attacked because
of their low one-electron reduction potential relative to that of the other three bases (Table
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1.2).20-22 That reduction potential becomes even lower for the 5’ guanine residue when a
run of guanine residues is present in a DNA sequence (Table 1.2). The most widely
recognized lesion formed by a one electron abstraction from a guanine residue is 7,8dihydro-8-oxo-2’-deoxyguanosine (8-oxoG) (Figure 1.2).20 When an electron is
abstracted from the C8 position of a guanine, a radical cation is formed. Water then acts
as a nucleophile and attacks the charged C8 position. The C8 hydrogen leaves along with
a second electron giving an 8-oxoG residue.19
An alternate explanation for Cr(VI) induced oxidative DNA damage that has also
been extensively investigated involves the formation of reactive oxygen species (ROS).
Through Fenton-like reactions (Figure 1.3) with H2O2, both Cr(III)20 and Cr(VI)21,22 have
been shown to be capable of producing hydroxyl radicals which can then attack the
electron rich aromatic rings of the nucleobases. This pathway is favorable in the presence
of high concentrations of H2O2 ([0.5 mM – 27 mM])20-22 which have been used for in
vitro studies. Under normal physiological conditions, the concentration of H2O2 in a cell
is much lower than 1 mM (in the µM range)23 indicating that oxidation of nucleic acids by
ROS is likely to play a very small role in the overall oxidative damage that has been
observed in cells exposed to Cr(VI).

Table 1.2 – Reduction potentials for nucleosides and DNA sequences.24,26,27 The 5'
guanine in a run of guanine residues has a lower reduction potential than a single guanine
and the 8-oxoG has a lower reduction potential than the parent guanine residue.
Nucleoside
Guanine (G)
Adenine (A)
Cytosine (C)
Thymine (T)
8-oxoG

Eo (V vs NHE)
1.29
1.42
1.6
1.7
0.74

DNA Sequence
GGG
GG
GA
GC
GT
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Eo (V vs NHE)
0.64
0.82
1.00
1.15
1.16
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H

N

HO

N
R

H2O

NH
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b
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NH2

N
- e- H+
O

H
N
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O
N
H

N

NH2

d

Figure 1.2 – Single electron oxidation of a guanine residue to give the 8-oxoG lesion.19

Cr(VI) +
Cr(V)
Cr(VI) +
Cr(IV)

1e-

Cr(V)

H2O2

Cr(VI)

2e-

Cr(IV)

H2O2

Cr(V)

OH

OH

OH

OH

Figure 1.3 – The Fenton-like reactions that have been proposed for chromium
metabolism within a cell. Hydroxyl radicals formed in these reactions could directly
abstract an electron from DNA.

8-oxoG has previously been viewed as the primary marker of oxidative stress.28
The 8-oxoG lesion, if allowed to persist in the genome, is mutagenic as it can cause a
mispairing with adenine during DNA replication causing G:C→T:A transversion
mutations.29 However, the one-electron reduction potential of 8-oxoG is even lower than
that of the parent guanine residue making it a prime target for further oxidative events
(Table 1.2). It would be highly unlikely for an electron to be directly abstracted from the
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same DNA base twice but further oxidized products of 8-oxoG have been observed both
in vitro and in cellular systems.30,31 Charge transfer is one mechanism that has been
proposed to explain how two oxidative events can occur at the same base in a DNA
sequence. This mechanism proposes that an electron hole will be translated through the
DNA to a sink – a nucleoside with a lower reduction potential than that of the neighboring
nucleosides.26 The stacked bases create an array of overlapping π-orbitals that facilitate
charge transfer through a DNA sequence.32 8-oxoG lesions can act as a sink for charge
transfer because of their lower reduction potential relative to that of the four undamaged
nucleosides. When an 8-oxoG lesion is present within approximately 10-20 base pairs
(greatly dependent on the DNA sequence)32 of the site of an electron abstraction from a
nucleobase, the resultant charge can be transferred to an 8-oxoG residue resulting in a
secondary oxidative event at the same base.
The low reduction potential of 8-oxoG along with its ability to act as a sink for
charge transfer in a DNA sequence indicates that 8-oxoG is not likely to be the end
product of an oxidative attack on the nucleobases. One of the secondary lesions that has
been shown to form both in vitro and in cellular systems is spiroiminodihydantoin
(Sp).30,31 Sp, like 8-oxoG, can produce G:C→T:A transversion mutations but at a higher
level. In addition to the G:C→T:A transversion mutations, Sp can also produce
G:C→C:G transversion mutations and polymerase arrest both in vitro and in cellular
systems.33-35 The formation of Sp helps to explain the high level of mutations observed in
Cr(VI) treated systems that cannot be accounted for by the formation of 8-oxoG lesions
alone.
There are a host of further oxidized lesions that have been proposed to form
following oxidation of DNA. Some of the more common examples are shown in figure
1.4. Sp is a further oxidized lesion of particular interest because it has been observed to
form in cellular systems,31 it has an increased mutagenic potential over that of 8-oxoG,
and it has been shown to accumulate in much larger quantities than 8-oxoG in an
Escherichia coli repair deficient model exposed to Cr(VI).31 Accumulation of Sp in a
cellular system is possible because while water may not be the strongest nucleophile
present in a cell it is the most abundant and can thus attack the radical cation formed
when an electron is abstracted from an 8-oxoG residue (Figure 1.5).30 Further more, Sp
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forms ideally at

37o C and at pH 7.430 which are both biologically relevant parameters.

Because it is more favorable for further oxidized lesions such as Sp to be the end product
of an oxidative event at a nucleobase, these lesions may serve as more relevant
biomarkers for oxidative stress in a cellular system.
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Figure 1.4 – A sample of some of the further oxidized guanine lesions that have been
proposed to form in oxidatively damaged DNA.
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Figure 1.5 – Single electron reduction of 8-oxoG to give the Sp lesion.30

1.3

Base Excision Repair
Cells have three types of repair systems in place to deal with damaged or

mismatched DNA bases which are conserved from prokaryotes to mammals.36 They
include base excision repair, nucleotide excision repair, and mismatch repair.37 Base
excision repair (BER) is the direct removal of a single nucleobase that is damaged or
mismatched.37 Nucleotide excision repair (NER) is the direct removal of a short sequence
of DNA (~25-30 bases) containing a damaged or mismatched base(s).37 Mismatch repair
(MMR) is the direct removal of a large sequence of DNA (up to a few kilodaltons in size)
that contains a mismatched base(s) following DNA replication.37 Cells primarily use the
BER pathway to remove oxidative DNA base lesions.38 The BER pathway involves a
DNA glycosylase that recognizes an individual damaged base. The damaged base is then
flipped out of the DNA strand and cleaved at the glycosidic bond forming an
apurinic/apyrimidinic (AP) site.38 The DNA glycosylase binds to the 1’ carbon of the
deoxyribose subunit allowing the damaged nucleobase to leave and a Schiff base to be
formed between the abasic site and the BER enzyme.38 Many DNA glycosylases do not
further process the AP site but some glycosylases involved in repair of oxidized DNA
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base lesions possess lyase activity allowing them to further degrade the AP site.39 Further
degradation leads to release of the DNA glycosylase and the formation of a 5’phosphomonoester and a 3’-unsaturated deoxyribose phosphate residue, also referred to
as the β-elimination product (Figure 1.6 c).39

Base

O
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P

O
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O
H

O-

H

O

a
O
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O

P

deglycosylation

H

H

O
O

OH
H

O-

H

H

H
DNA Glycosylase

H

O

b
O

P

DNA Glycosylase
+ Base

O

OR

OR
O
OR

c

P

OH

O

OH
O

OH

O

P

O

+ DNA Glycosylase

OR

Figure 1.6 – General reaction mechanism of a DNA glycosylase with β-lyase activity.
Structure c is the β-elimination product.

Cells have a variety of genes that encode for DNA glycosylases that repair
specific oxidative damage to the nucleobases. 8-oxoG is a major product of a single
electron oxidative event at a guanine residue24 and is formed frequently in cellular
DNA.25 Therefore, cellular systems are well-equipped to deal with 8-oxoG formation.
Table 1.3 outlines the various bacterial BER enzymes responsible for the removal of 8oxoG lesions and their mammalian homologues. The bacterial glycosylases include
MutM which excises 8-oxoG lesions formed within a DNA sequence40,41 and MutY
which excises an adenine paired with an 8-oxoG residue42 which will occur following a
round of replication. MutT degrades 8-oxoGTP to the monophosphate before it can be
incorporated into the genome.43 OGG1 is the mammalian glycosylase which is
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homologous to the bacterial glycosylase MutM.44 8-oxoG was considered to be the major
DNA base lesion caused by oxidative stress until just recently and OGG1 was considered
to be the major repair enzyme for oxidative DNA damage in mammalian systems.
Studies conducted with OGG1 deficient mice have shown that 8-oxoG lesions accumulate
in genomic DNA at a rate of nearly 10-100 fold as compared to OGG1 proficient
mice.45,46 Despite the fact that such high levels of 8-oxoG were observed to accumulate
in OGG1 deficient mice, the spontaneous mutation rate in those mice was relatively low
and no tumor formation was detected.45 However, there are many oxidants that are
known to induce tumor formation so based on studies conducted with OGG1 deficient
mice, it can be reasoned that 8-oxoG is not likely the major oxidative base lesion leading
to cancer initiation in cells exposed to oxidants. Further oxidative nucleobase lesions
produce higher mutation rates than 8-oxoG33-35 and therefore have the potential to play a
more significant role in cancer initiation than 8-oxoG.

Table 1.3 – BER glycosylases known to repair Cr(VI) induced nucleobase lesions.47
Some of these glycosylases are known to repair additional lesions not listed here but those
additional lesions are not associated with Cr(VI) induced genetic damage.
BER Glycosylase

Nucleobase Lesion Substrates

Mammalian Homolog

MutM (Fpg)

8oxoG:C, Sp:C, Gh:C, 8oxoG:G, Sp:G,

OGG1

Gh:G
MutY

8oxoG:A, G:A

MYH

MutT

8oxo dGTP, 8oxo dATP

NTH1

Nei

Sp:A, Gh:A, 8oxoG:C, Sp:C, Gh:C,

NEIL1, NEIL2, NEIL3

8oxoG:G, Sp:G, Gh:G

With the discovery of further oxidized DNA lesions such as Sp came the
discovery of DNA glycosylases that recognize and cleave those further oxidized DNA
lesions. Endonuclease VIII (Nei) is a bacterial glycosylase that has been shown to repair
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further oxidized DNA lesions including Sp.48,49 Nei deficient E. coli have been shown to
accumulate Sp lesions but not 8-oxoG lesions following chromate exposure (Figure
1.7).31 This indicated that the Nei repair enzyme is directed specifically at further
oxidized lesions. Recently, three mammalian homologues of the Nei gene were identified
and labeled Neil1, Neil2, and Neil3 (Nei-Like).50,51 NEIL1 and NEIL2 have been shown
to recognize the further oxidized DNA lesion Sp and NEIL1 was shown to cleave Sp in
both single and double stranded oligonucleotides.49 We expected that NEIL1 deficient
mammalian cells would accumulate Sp lesions and be less resistant to Cr(VI) as was
observed in the Nei deficient E. coli studies. However, as this thesis will demonstrate,
NEIL1 plays a much more complex role in mammalian cells that just BER creating a
different outcome than initially hypothesized.

Figure 1.7 – Sp accumulation in Nei deficient E. coli over their wild type counterpart but
not in MutM/MutY deficient E. coli over their wild type counterpart. Taken from [31].
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CHAPTER 2
Characterization of a NEIL1 Deficient Cell Line

2.1

Introduction
The NEIL1 BER glycosylase was first described in the literature in 2002.1-4 The

Neil1 gene maps to the 15q22 chromosome location in humans.5 Deletions in the 15q
chromosome arm are observed in more than 70% of human small cell lung carcinomas.5
Substrates for NEIL1 include DNA base lesions such as formamido-pyrimidines (FapyG
and FapyA), thymine glycol, and 5-hydroxyuracil.1-3,6 These lesions are associated with
oxidative base damage so it was thought that NEIL1 may also be capable of cleaving
some of the oxidative base lesions which form following exposure of DNA to chromate.
Of particular interest were the hydantoin lesions as they had previously been shown to
form directly from 8-oxoG lesions in synthetic oligonucleotide systems exposed to single
electron oxidants.7-9,16 The specific activity of NEIL1 and NEIL2 in excising
spiroiminodihydantoin (Sp), guanidinohydantoin (Gh), and 8-oxoG lesions has been
studied using purified NEIL1 and NEIL2 enzymes.10 These studies have shown that
NEIL1 but not NEIL2 will cleave Sp lesions from duplex DNA (Figure 2.1a).10 NEIL2
was capable of cleaving Sp from single-stranded oligonucleotides and could recognize but
not cleave Sp in duplex DNA (Figure 2.1b).10 Both enzymes showed little or no affinity
for the 8-oxoG lesion.10
The NEIL glycosylases harbor intrinsic lyase activity that allows them to complete
βδ-elimnation (Figure 2.2) at an apurinic/apyrimidinic (AP) site unlike OGG1.11 OGG1
also possesses intrinsic lyase activity that would allow it to carry out β-elimination at an
AP site following glycosidic bond cleavage.12 However, this lyase activity is weak and
OGG1 is typically out competed for the AP site by apurinic/apyrimidinic endonuclease
(APE).11 The βδ-elimnation product formed by further processing of the AP site by
NEIL1 or NEIL2 has both a 5' and 3' phosphate termini.13 APE will not recognize a free
3' phosphate suggesting that the NEIL1 and NEIL2 cleavage products must be processed
differently than through the typical APE-dependent pathway. In fact, it has been shown
that the 3' phosphate can be removed by DNA 5'-kinase/3'-phosphatase – polynucleotide
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kinase (PNK)14 - providing the alternative pathway needed to complete processing of the
damaged site prior to reinsertion of a new base by a DNA polymerase.

Figure 2.1a – The NEIL1 glycosylase cleaves Sp paired with any of the four natural
DNA bases. A δ-elimination product was observed in a duplex DNA system. Taken from
[10].

Figure 2.1b – The NEIL2 glycosylase is unable to cleave the Sp lesion in duplex DNA
regardless of which natural DNA base it is paired. Taken from [10].

Armed with the knowledge that NEIL1 and NEIL2 are capable of cleaving
secondary oxidative lesions from chromate damaged DNA, a system was developed to
monitor intracellular lesion accumulation. OGG1 is the mammalian homolog of MutM
and NEIL1 and NEIL2 are mammalian homologues of Nei. A MutM-/MutY- double
knock-out and Nei deficient E. coli cell lines were exposed to chromate and their DNA
was monitored for accumulation of 8-oxoG and Sp lesions.15 The Nei deficient cell line
was shown to have elevated sensitivity to chromate and to accumulate Sp lesions but not
8-oxoG lesions as was observed in the MutM-/MutY- double knock-out.15
20
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Figure 2.2 – βδ-elimination scheme that is carried out by the NEIL1 and NEIL2
glycosylases.13

A Neil1-/- mouse was engineered using a null-gene knock out plasmid which was
inserted into the Neil1-coding region.16 The Neil1-/- mice developed a number of
metabolically related problems including obesity, fatty liver disease, kidney
vacuolization, hyperleptinemia, hyperinsulinemia and increased mitochondrial DNA
damage.16 All of these conditions can be linked to genetic damage initiated by reactive
oxygen species (ROS) and therefore indicated that cells from a Neil1-/- mouse line should
be more sensitive to oxidative stress than their wild type counterparts. Kidney epithelial
cells from both the wild type and Neil1-/- mouse lines have been generously donated
allowing us to analyze the effects of chromate exposure in a NEIL1 deficient mammalian
system.
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To begin our studies with the NEIL1 cell lines, we first analyzed the cells for the
presence or absence of an uninterrupted Neil1 gene and then for their ability to excise 8oxoG and Sp lesions from duplex DNA. We expected to observe cleavage of the 8-oxoG
lesion by both the wild type and Neil1-/- cell lines as the mOGG1 gene was unmodified in
both cell lines. Without the presence of a functional Neil1 gene however, we predicted
that the Neil1-/- cell line would be unable to cleave Sp lesions. Our results however
demonstrated that Sp can still be cleaved by cellular extracts devoid of functional NEIL1
enzyme indicating that NEIL1 may not be solely responsible for excision of Sp lesions in
a cellular environment.

2.2

Materials and Methods

2.2.1

Murine Cell Growth Conditions

Neil1+/+, Neil1+/-, and Neil1-/- murine

kidney epithelial cells were obtained from Dr. Steven Llyod at the Oregon Health and
Science University (Portland, OR). All three cell lines were grown in DMEM containing
4.5 g/L D-glucose, L-glutamine, and 110 mg/L sodium pyruvate (Gibco) which was
supplemented with 15% fetal calf serum (HyClone) and 1% 100X antibiotic-antimycotic
(Gibco). Cells were maintained at 37o C under an atmosphere of 5% CO2 to maintain a
constant pH.

2.2.2 DNA Extraction

Media was removed and discarded from flasks in

which cells had formed a complete monolayer. The cells were rinsed with 1X PBS
(Sigma) and harvested by treatment with Trypsin-EDTA (Gibco). The cell samples were
pelleted at 300 x g and the supernatant was discarded. Samples were placed in 15 mL
conical tubes which were placed on ice followed by the addition of 1 mL of 4o C DNA
extraction buffer (0.1 M Tris-HCl, 0.1 M NH4Cl, pH 8.0) to each sample. Cell pellets
were mixed thoroughly but gently and then sonicated for 5 min. in a Branson 3200
sonicating water bath. Cell samples were pelleted at 2400 x g (4o C) for 5 min. and the
supernatant was discarded. Pellets were resuspended in 300 µL of DNA extraction buffer
containing 33 U of RNAse T1 (Sigma) and 200 µg of RNAse A (Sigma). After 1 hour of
incubation at 37o C, 300 µL of DNA extraction buffer containing 300 µg of Proteinase K
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(Invitrogen) and 1% SDS (Gibco) was added. The samples were again mixed thoroughly
but gently and allowed to incubate for an additional 1 hour at 37o C. 750 µL of
concentrated, buffered phenol (pH 7.9, Sigma) was then added and each sample was
thoroughly mixed before being centrifuged at 2400 x g for 5 min. The top layer was
removed and placed into a fresh 1.5 mL tube, mixed with 250 µL of a 25:24:1 phenol :
chloroform : isoamyl alcohol solution (pH 7.9, EMD), and centrifuged at 12000 x g for 5
min. Again the top layer was removed and placed into a fresh 1.5 mL tube, mixed with
250 µL of a 24:1 chloroform : isoamyl alcohol solution (Sigma), and centrifuged at 12000
x g for 5 min. The top layer was mixed with 30 µL of 10 M ammonium acetate (pH 5.0)
and 1 mL of -20o C 100% ethanol in a fresh 1.5 mL tube. Samples were mixed and
allowed to precipitate at -20o C overnight before being pelleted at 12000 x g (4o C) for 15
min. The supernatant was discarded, the pellet was washed with 1 mL of 70% ethanol,
and re-centrifuged at 12000 x g (4o C) for 10 min. Residual ethanol was dried and the
pellet was resuspended in 100 µl of deionized water. Absorbance at 260 nm (OD260) was
obtained in order to determine the DNA content of each sample.

2.2.3

Genotyping NEIL1 Cell Lines

A PCR reaction was run for a DNA

sample from each cell line using the same forward Neil1 primer and a two different
reverse primers specific for either the wild type Neil1 gene or the interrupted form. The
forward primer used for both genotypes was derived from Neil1 intron 1 to Neil1 exon 2,
5'-CAC CAG TGA GCA AGA CAG CCA T-3'. A reverse primer for the Neil1+/+
genotype was developed from codons 6-12 in the Neil1 gene which were interrupted in
the Neil1-/- genotype, 5'-GTG GCT GGC CAG GTG CAG CTC-3'. A reverse primer for
the Neil1-/- genotype was developed from the neomycin open reading frame (ORF) that
was used to interrupt the Neil1 gene, 5'-CCA GCT CAT TCC TCC CAC TCA-3' (Figure
2.3a). Template DNA (500 ng) was reacted with 2.5 U of Taq DNA polymerase
(Novagen) in a solution of 16 nM forward Neil1 primer (Integrated DNA Technologies),
0.2 mM dNTP mixture (New England Biolabs), 1.5 mM MgCl2 buffer (Novagen), and 16
nM of either the wild type or knock-out Neil1 reverse primer (Integrated DNA
Technologies). The reaction underwent 35 rounds of PCR amplification in a PTC-200
Peltier Thermocycler. Amplified DNA samples were loaded onto a 1.2% agarose gel
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containing 0.5 µg/mL ethidium bromide. Samples were loaded in a 30% glycerol buffer
supplemented with 0.25% xylene cyanol (Sigma) and 0.25% bromophenol blue (Aldrich).
The gel was run in a Tris-Borate buffer (0.045M Tris-Base, 0.045 M Borate, 0.001 M
EDTA) at 90 V for 1.5 hours. PCR product bands were visualized using a Fujifilm FLA3000 phosphoimager.

2.2.4

Sp Oligonucleotide Synthesis

A 22 base pair (bp) oligonucleotide

containing a single 8-oxoG lesion (5'-ACC AGC AGC 8-oxoGGC CGC ACC AGT G-3')
was purchased from TriLink Biotech. This oligonucleotide was oxidized using Cr(V) –
Salen which was synthesized by reacting Cr(III) – Salen with iodosylbenzene in a 1:2
molar ratio respectively in dry acetonitrile for 15 min. at room temperature.17 Each
oxidation reaction consisted of 0.1 mM 8-oxoG oligonucleotide, 10 mM phosphate buffer
at pH 7.4, and 0.8 mM Cr(V) – Salen. The reaction was allowed to proceed for 40 min. at
37o C. Upon completion of the reaction, the resulting Sp oligonucleotide was isolated on
a Dionex NucleoPac PA-100 4 mm x 250 mm anion exchange column. A linear gradient
was employed over 18 minutes from 90% mobile phase A (10% aqueous acetonitrile) and
10% mobile phase B (1.5 M ammonium acetate, pH 6.0 in 10% aqueous acetonitrile) to
100% mobile phase B. Sp containing oligonucleotide fractions were collected, combined
and concentrated.

2.2.5
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P Labeling and Annealing of Oligonucleotides

Oligonucleotide concentrations were obtained by measuring an OD260 for the synthesized
Sp oligonucleotide and the 8-oxoG oligonucleotide. A control oligonucleotide with a
normal guanine residue present in place of the 8-oxoG lesion and a complement
oligonucleotide were purchased from Integrated DNA Technologies and the concentration
of each was determined in the same way. Equivalent molar concentrations of the Sp, 8oxoG, and control oligonucleotides were 5' labeled with 32P-γ-ATP (GE Health Care).
Each reaction consisted of 10 U of polynucleotide kinase (Promega) 10 µCi 32P-γ-ATP
and 1X polynucleotide kinase buffer (Promega). Excess 32P-γ-ATP was removed using a
P6 Micro Bio-Spin Chromatography Column from BioRad. A 20% excess of the
complement oligonucleotide was added to each of the three labeled oligonucleotide
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solutions. These were then annealed by heating to 95o C for 5 min. before being cooled
slowly (~1o C/5 min.) to room temperature. Once annealed, the solutions were stored at
4o C and used as a stock solution for up to a week.

2.2.6

Nuclear Extract Preparation

Both NEIL1 deficient and wild type

epithelial cells were harvested by gently scraping them from 75 cm2 flasks with a cell
scraper after being rinsed with ice cold 1X PBS containing phosphatase inhibitors.
Nuclear extracts were then isolated using the Nuclear Extract Kit from Active Motif. A
20 µL aliquot of nuclear extracts from each cell line was retained to determine protein
concentrations. The Bicinchoninic Acid Protein Assay Reagent Kit (Pierce) was used to
determine protein concentrations. The remainder of the nuclear extracts were stored at
-80o C in 25 µL aliquots.

2.2.7 Sp Cleavage Assay

Nuclear extracts were thawed immediately prior to

use in the cleavage assay. Reaction buffer for the cleavage assay was composed of 20
mM Tris-HCl (GibcoBRL) pH 8.0, 1 mM ethylenediaminetetraacetic acid (EDTA,
Sigma), 1 mM Dithiothreitol (DTT, Fisher), and 100 µg/mL DNAse free Bovine Serum
Albumin (New England Biolabs). 500 nM concentrations of each annealed
oligonucleotide were reacted with 40 µg of nuclear extracts at 37o C. 500 nM
concentrations of each annealed oligonucleotide were also reacted with 0.8 U of purified
hOGG1 (New England Biolabs) as a control for 8-oxoG cleavage. 5 µL aliquots of the
reaction solutions were removed at 0, 60, 90 and 120 min. Each aliquot was immediately
quenched by adding 5 µL of a formamide denaturing loading dye (1 mL formamide
(Fisher), and 1 mg/mL bromophenol blue (Aldrich)) that had been preheated to 95o C.
These were allowed to denature at 95o C for 5 min. and were then placed on ice for 3 min.
immediately prior to being loaded onto a pre-poured 15% TBE, 7 M urea pre-poured gel
(Invitrogen). The gel was run in a Tris-Borate-EDTA buffer (45 mM Tris Base (Aldrich),
45 mM Boric Acid (EMD Biosciences), and 0.001 M EDTA (Sigma)) for 40 min. at 180
V. Gels were visualized on a Fujifilm FLA-3000 phosphoimager.
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2.3

Results

2.3.1

Genotype Analysis

Primer sequences for the Neil1+/+ and the Neil1-/-

genotypes were provided by Dr. Stephen Llyod (Figure 2.3a). The expected PCR
fragment lengths were 268 bp for the Neil1+/+ genotype, 448 bp for the Neil1-/- genotype
and both a 268 bp fragment and a 448 bp fragment for the Neil1+/- genotype. A
representative gel is shown in figure 2.3b.

EcoRI

5’ UTR

forward
primer

A
Intron 1

Exon 1

EcoRI

3’ Region

Exon 2

codons 6-12
reverse primer

79 bp deletion
from exon 1
EcoRI

5’ UTR

B
forward
primer

EcoRI

Neo

PGK

Exon 1

Intron 1

Exon 2

EcoRI

3’ Region

reverse
primer
Figure 2.3a – Neil1 gene showing primer locations in both the wild type and interrupted
form of the gene. The reverse primers are derived from exon 1. Codons 6-12 make up
the wild type reverse primer (A). The knock out reverse primer is derived from the
neomycin resistance gene that is inserted into the 5’ region of exon 1 in the Neil1-/- gene
(B). This insertion causes a 79 bp deletion from the 5’ end of exon 1 and includes the
neomycin open reading frame (Neo) and a phosphoglycerate kinase promoter (PGK).16
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1000 bp
750 bp
500 bp
400 bp

448 bp

300 bp
268 bp

200 bp

Figure 2.3b –PCR products corresponding to the three murine kidney epithelial cell lines.
Lanes 3-10 all include the forward Neil1 primer. Lanes: 1 - molecular weight marker, 2 empty, 3 - no template with Neil1+/+ reverse primer, 4 - no template with Neil1-/- reverse
primer, 5 - Neil1+/+ template with Neil1+/+ reverse primer (268 bp product), 6 - Neil1+/+
template with Neil1-/- reverse primer, 7 - Neil1-/- template with Neil1+/+ reverse primer, 8 Neil1-/- template with Neil1-/- reverse primer (448 bp product), 9 - Neil1+/- template with
Neil1+/+ reverse primer (268 bp product), 10 - Neil1+/- template with Neil1-/- reverse
primer (448 bp product).

2.3.2 Sp Cleavage Assay

The original 8-oxoG 22-mer was purified on a

Dionex NucleoPac PA-100 4 mm x 250 mm anion exchange column under the same
separation conditions mentioned previously for the oxidized Sp 22-mer. The 8-oxoG 22mer eluted after 11.7 min. (Figure 2.4a). This peak was collected and concentrated before
being oxidized with Cr(V) – Salen to form the Sp 22-mer. Figure 2.4b is the HPLC trace
from the product of the oxidized 8-oxoG 22-mer. The oxidation reaction was not
cleaned-up prior to separation by HPLC resulting in a significant peak at 1.3 min.
representing residual reaction components in the buffer front. Two small peaks with
retention times of 9.8 and 10.2 min. represent a small amount of Gh/Ia 22-mer. Residual
8-oxoG 22-mer eluted at 11.5 min. while the two peaks representing the Sp 22-mer eluted
at 13.1 and 13.5 min. When synthesized in single-stranded DNA, Sp will form two
isomers (Figure 2.4b). The identity of these three sets of peaks has been confirmed in
previous studies using ESI-MS analysis.18
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Purified hOGG1 enzyme, as well as 40 µg of nuclear extracts from both the
Neil1+/+ and Neil1-/- cell lines, were reacted with a control 22-mer, an 8-oxoG containing
22-mer, and an Sp containing 22-mer. The hOGG1 enzyme was unable to cleave the
control substrate or the Sp substrate but showed very efficient cleavage of the 8-oxoG
substrate (Figure 2.5-1). Both the Neil1+/+ and Neil1-/- nuclear extracts were unable to
cleave the control substrate but cleaved both the 8-oxoG and the Sp substrate (Figure 2.52,3). A single 12 bp product was observed in all of the reactions for which cleavage
occurred.

DAD1 A, Sig=260,4 Ref=550,100 (KENT\2-12_3.D)

8-oxoG 22-mer
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4000
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Figure 2.4a – HPLC trace of the oligonucleotide containing a single 8-oxoG lesion.
Retention time was 11.7 minutes.
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Figure 2.4b – HPLC trace of the oligonucleotide containing a single 8-oxoG lesion after
oxidation by Cr(V) – Salen. Residual 8-oxoG 22-mer elutes at 11.5 minutes. The two
peaks that elute at 13.1 and 13.5 minutes represent the two 22-mer oligonucleotides
containing each of the two Sp isomers.

Figure 2.5 – Gel 1 shows the reaction between purified hOGG1 and a 22 bp substrate.
Gel 1: a) lesion-free substrate, b) 8-oxoG substrate, c) Sp substrate. Gel 2 shows the
reaction between Neil1+/+ nuclear extracts and a 22 bp substrate. Gel 2: a) lesion-free
substrate, b) 8-oxoG substrate, c) Sp substrate. Gel 3 shows the reaction between Neil1-/nuclear extracts and a 22 bp substrate. Gel 3: a) lesion-free substrate, b) 8-oxoG
substrate, c) Sp substrate. Double bands in the substrate region occurred due to
incomplete denaturation of oligonucleotides prior to electrophoretic separation.
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2.4

Discussion

2.4.1

Genotype Confirmation

The genotype of each of the kidney epithelial

cell lines was confirmed upon receipt of the cells. The Neil1+/+ cell line produced only a
268 bp PCR amplified product confirming that it did indeed have two unaltered copies of
the Neil1 gene. The Neil1+/- cell line produced both a 268 bp and a 448 bp PCR amplified
product indicating that it possessed one uninterrupted copy of the Neil1 gene and one
interrupted Neil1 gene copy. Finally, the Neil1 -/- cell line produced only the 448 bp PCR
amplified product confirming that both copies of the Neil1 gene had been successfully
interrupted with the neomycin open reading frame. Many of our subsequent studies were
conducted without use of the heterozygous cell line.

2.4.2

Sp Cleavage in a NEIL1 Deficient Cell Line

A control reaction

between a lesion-free DNA substrate and hOGG1 enzyme or the NEIL1 proficient and
deficient nuclear extracts ensured that there was no spontaneous DNA cleavage occurring
due to reaction conditions. A second control reaction using the 8-oxoG DNA substrate
showed that all three systems were able to excise the 8-oxoG lesion in duplex DNA. This
was the expected result as 8-oxoG is the primary target lesion for hOGG1 and because the
mOGG1 gene was unaltered in both the wild type and Neil1-/- cell lines. Based on studies
conducted with purified NEIL1 enzyme showing that only NEIL1 and not NEIL2 could
excise Sp lesions in duplex DNA, we hypothesized that a NEIL1 deficient cell line may
not be capable of cleaving Sp lesions from duplex DNA. Our results, however,
demonstrated that the NEIL1 deficient as well as the NEIL1 proficient nuclear extracts
were able to cleave the Sp lesion from duplex DNA. The signal intensity of the cleaved
12 bp Sp product looks similar between Gel 2 and 3 in figure 2.5. However, the intensity
of the 12 bp Sp product relative to that of the 12 bp 8-oxoG product on Gel 3 is much
lower than that of the same comparison made on Gel 2. This indicates that while the
NEIL1 deficient nuclear extracts may be cleaving the Sp lesion, they are not cleaving Sp
as efficiently as the NEIL1 proficient nuclear extracts. There are several possible
explanations for the Sp cleavage seen in the NEIL1 deficient nuclear extract reactions. It
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is likely that all three of the following explanations contribute to this observed Sp
cleavage.
First, there may be a small amount of 8-oxoG substrate present in the Sp substrate
lane. It is possible that the shoulder on the 8-oxoG 22-mer peak runs into the Sp peaks as
they are separated by HPLC (Figure 2.4b). This proposal is based on the fact that in some
of the cleavage gels, a faint 12 bp product band was visible in the Sp substrate lane for the
purified hOGG1 reaction. While some OGG1 homologues such as yeast OGG1 and
OGG2 are capable of cleaving the Sp lesion in duplex DNA, the human form – hOGG1 –
does not recognize the Sp lesion19 and hOGG1 is unable to excise Sp from duplex DNA
paired with any of the four natural bases.18 This fact suggests it is unlikely that the faint
cleavage product seen in the Sp substrate lane for the hOGG1 reaction is actually a 12 bp
DNA fragment containing the Sp lesion. There is also a small possibility that there may
be some Gh/Ia substrate present as well. This is much more unlikely than having 8-oxoG
substrate contamination as the Gh/Ia substrate elutes prior to both the 8-oxoG and Sp
substrate when separated by HPLC (Figure 2.4b). This type of contamination, however,
would not account for the faint cleavage product observed in the Sp substrate lane for the
hOGG1 reaction as hOGG1 also has little or no affinity for the Gh/Ia lesion in duplex
DNA.18 Thus, it is most likely that the small amount of product observed in the hOGG1
reaction with the Sp substrate is a small amount of 8-oxoG substrate contaminating that
reaction lane. The amount of cleavage product observed in the NEIL1 deficient nuclear
extract reaction with the Sp substrate was much more extensive than that observed for the
hOGG1 reaction with that same substrate based on relative product intensities. This
indicates that 8-oxoG substrate contamination does not account for all of the observed Sp
cleavage by the NEIL1 deficient nuclear extracts.
Secondly, the NEIL2 enzyme may be capable of excising the Sp lesion in vivo.
NEIL2 was not capable of excising Sp from duplex DNA,10 however, purified NEIL2
was capable of excising Sp from a single-stranded oligonucleotide and was able to
recognize the Sp lesion in duplex DNA as demonstrated by a protein trapping assay.10 It
is reasonable to then suggest that the NEIL2 enzyme may be capable of excising the Sp
lesion when functioning in a complete cellular system probably by recruiting downstream
proteins of the BER apparatus. Unlike the in vitro NEIL1 and NEIL2 cleavage set-up, the
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nuclear extracts used in our cleavage assay contain a wide variety of proteins capable of
aiding in the BER process. For example, the OGG1 enzyme has the ability to carry out βelimination at an AP site but it is much less efficient at this step than APE1.20,21
Therefore, in a cellular system, OGG1 will be displaced by APE1 which will then remove
the sugar residue preparing the AP site for insertion of a new base.20 Not much is yet
know about NEIL1 and NEIL2 enzymatic functioning in a whole cell environment but it
is likely that there are a variety of cellular proteins (for example DNA 5'-kinase/3'phosphatase) that may be able to assist NEIL1 and/or NEIL2 making it possible for these
BER enzymes to excise lesions in vivo that they are incapable of cleaving without the aid
of accessory proteins.
Thirdly, Mismatch Repair (MMR) may also be playing a role in excising the Sp
lesion in vivo. Typically MMR recognizes mismatched base pairs because they create a
distortion in the DNA backbone. This distortion is usually quite small as it just involves a
few misplaced hydrogen bonds between base pairs. The 8-oxoG lesion is not repaired by
MMR because it does not create enough of a distortion in the DNA backbone to be
recognized by MMR proteins as it simply shifts the N7 from a hydrogen bond acceptor to
a hydrogen bond donor position. The Sp lesion however, may be able to recruit both BER
and MMR proteins. Sp is small enough for BER enzymes to recognize and cleave it from
duplex DNA. However, unlike 8-oxoG, Sp creates a more significant distortion in the
DNA backbone (Figure 2.6) since Sp does not maintain a planar conformation like the
natural DNA bases and 8-oxoG. This distortion is similar in magnitude to that seen with
ternary Cr-DNA adducts and MMR has been shown to recognize DNA bending caused by
ternary Cr-DNA adducts22 which do not create a large enough distortion to recruit
Nucleotide Excision Repair (NER) proteins but are too bulky for BER enzymes. Sp is
probably not so bulky as to cause a DNA helix distortion large enough to recruit NER
proteins but it may be enough of a distortion to recruit MMR proteins in addition to BER
enzymes.
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Figure 2.6 – The spiroiminodihydantoin lesion is composed of two imidazole rings which
sit at a 90o angle to one another distorting the π-stacking structure of normal B-form
DNA.

2.5

Conclusions
We were able to confirm that the NEIL1 deficient cell line did not carry a

functional copy of the Neil1 gene. Based on that finding and the results of studies carried
out with purified NEIL1 and NEIL2 glycosylases, we anticipated that the NEIL1 deficient
murine epithelial cells would be unable to excise the Sp lesion from duplex DNA. This
did not turn out to be true although the efficiency of Sp excision from duplex DNA is
reduced in the NEIL1 deficient cells as compared to their wild type counterpart.
Therfore, we expected that the Neil1-/- cell line would be more sensitive to chromate than
the Neil1+/+ cell line. Since there was some Sp cleavage occurring in the Neil1-/- cell line,
we did not expect that the difference in sensitivity to chromate would be as pronounced as
that seen in Nei deficient E. coli.
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CHAPTER 3
The Effects of a NEIL1 Deficiency on Chromate Sensitivity and Cell Cycle
Regulation

3.1

Introduction
The eukaryotic cell cycle is composed of four distinct phases - G1, S, G2, and M

(Figure 3.1). The G1 and G2 phases are growth periods for the cell. During these phases,
the overall mass of the cell will increase as the majority of cellular proteins are
synthesized as well as organelles such as membranes, endoplasmic reticulum,
mitochondria, and ribosomes. Much of this growth prepares the cell to undergo a round
of division since duplicates of most cellular components must be synthesized prior to
replication. Between the two growth phases is the S phase, or DNA synthesis phase. It is
at this time that all of the genomic DNA will be replicated. The final stage of the cell
cycle is mitosis (M phase) – cell division. Mitosis is further broken down in to four
segments; prophase, metaphase, anaphase, and telophase. A rapidly replicating
mammalian cell will complete one full cell cycle every 24 hours.1 Roughly 12 hours are
spent in G1, 6 hours in S, 6 hours in G2, and 30 minutes in mitosis.1
The time spent in each phase of the cell cycle varies greatly between different
types of cells in multicelluar organisms. A 24-hour cell cycle is common for skin cells or
intestinal cells that are regenerated frequently.1 At the other extreme, neurons leave the
cell cycle permanently so will never divide during their life time. Neurons exit the cell
cycle during the G1 phase and enter a sub-phase referred to as G0 (Figure 3.1).1 Other
cells will also arrest at the G0 sub-phase but many can be stimulated to re-enter the main
cell cycle, such as liver cells that only need to be regenerated about once per year or
following damage to the liver tissue. This type of arrest is normal for cells that do not
need to replicate frequently. Some cells may also enter an arrest phase during the G2
period of growth as demonstrated by certain epidermal cells.1 Another reason that cells
may enter a cell cycle arrest sub-phase, is due to the accumulation of DNA damage. Four
checkpoints throughout the cell cycle lead to temporary or permanent cell cycle arrest or
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death.2 Three of these checkpoints are dedicated to monitoring DNA damage (Figure
3.2).2

G2 arrest phase
G0 phase

Figure 3.1 – The eukaryotic cell cycle. A growth period composed of the G1, S, and G2
phases is collectively referred to as interphase. Mitosis, or the phase of cell division,
completes the cycle. Cells can enter two arrest phases, G0 and G2 arrest as a way to
temporarily or permanently exit the cell cycle.

In the G1 phase, DNA is scanned to ensure that no damage was incurred during the
previous round of mitosis and that one copy of each chromosome was distributed to the
daughter nuclei. However, the DNA may also be damaged during G1 by an exogenous
factor such as chromate. The cell can then enter the G0 arrest phase while any genetic
damage is repaired. If repair is successful, arrested cells can then re-enter the cell cycle
and proceed into S phase. Following S phase, the DNA will again be monitored for
damage and to ensure that all DNA was properly replicated. If there is damage, the cell
will again be arrested but this time in the G2 arrest phase while the damage is repaired so
that the cell can then progress into mitosis.
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Checkpoint for
paired kinetochores
during mitosis

Checkpoint for
DNA damage
following synthesis
and prior to mitosis

Checkpoint for
damaged DNA
following division

Checkpoint for
DNA damage
prior to synthesis

Figure 3.2 – The cell cycle maintains checkpoints to monitor the integrity of DNA and
other cell components. If damage to cellular components is detected at these checkpoints,
the cell will either go into arrest followed by entering a survival mode where the damage
will be repaired or it will self-destruct via necrosis or apoptosis.

A cell is only capable of repairing so much genetic damage. With a mutagen such
as chromate, normal cells can survive following exposure to low concentrations of Cr(VI)
since they are equipped to repair the oxidative DNA lesions that will be formed. The
cells should go into a period of arrest, repair the damage and then reenter the cell cycle.
Exposure to very high concentrations of Cr(VI) may cause a cell to enter a necrotic
pathway. Necrosis is an unorganized form of cell death that will occur when a cell is
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physically disrupted or incurs severe metabolic damage.3 This pathway can be viewed as
a last resort as it can induce necrosis in many neighboring cells as well. As a necrotic
cells dies, its contents are rapidly released into the extracellular matrix and much of that
material can be toxic when not compartmentalized within a cell.3 A third, and more
common scenario is the apoptotic pathway. When cells are exposed to intermediate but
toxic concentrations of chromate, they can reach a point where they have too much DNA
damage to be effectively repaired but have not been poisoned so badly that they will enter
a necrotic pathway. At what point the damage becomes so great that a cell will be
diverted from a survival pathway into an apoptotic pathway is unknown.4 Instead, these
cells will undergo cell degradation in a tightly regulated cascade of events collectively
referred to as apoptosis.3
There are two apoptotic pathways, extrinsic and intrinsic.5 Both pathways are
regulated by the action of caspases (cysteine proteases)5 and converge once the apoptotic
cascade reaches the point of activation of the executioner caspases-2, 3, and 7.6,7 An
internal signal such as DNA damage induced by Cr(VI), activates the intrinsic apoptotic
pathway.5 The intrinsic pathway differs from the extrinsic in that the first signals for
apoptosis are generated at the mitochondria rather than at the cell membrane. p53, a
tumor suppressor protein, monitors DNA for damage.8 Once that damage reaches a
certain level, p53 will activate B-cell lymphoma 2 protein (Bcl-2) to form a dimer with
Bcl-2 associated X protein (Bax).9-11 The Bax protein will travel to the mitochondria,
associate with Bcl-2, insert itself into the outer membrane, and form a pore that allows
cations to freely flow into the negatively charged intermembrane space of the
mitochondria.3,12 This shift in voltage causes voltage-dependent anion channels (VDACs)
present in the outer mitochondrial membrane to open allowing cytochrome c to escape
into the cytoplasm.3,13 Cytochrome c will then bind to apoptotic protease activating factor
1 (Apaf1) to cleave caspase 9.14 This cascade of events (Figure 3.3) activates numerous
proteases and nucleases which will begin the orderly degradation of cellular proteins and
DNA.
Apoptosis helps to protect cells exposed to chromate from accumulating mutations
that could eventually lead to the initiation of cancer. Based on the information obtained
from the cleavage assays described in chapter 2, we hypothesized that a NEIL1
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p53 Protein Detects Excessive DNA Damage

Bcl-2 + Bax Dimerize Forming Mitochondrial Membrane Pore

Cytochrome C Released Into Cytoplasm Through VDAC's

Cytochrome C and Apaf1 Bind and Cleave Caspase 9

Activated Caspase 9 Cleaves Caspases 2,3 and 7
Intrinsic and Extrinsic Apoptotic
Pathways Meet Here
Cellular Proteins and DNA Are Degraded

Figure 3.3 – The intrinsic apoptotic pathway. The p53 protein detects excessive DNA
damage and initiates a cascade of events that lead to release of cytochrome C from the
mitochondria followed by activation of caspase 9. Activated caspase 9 will then cleave
and activate caspases 2,3, and 7 leading to the degradation of cellular proteins and DNA.
The intrinsic and extrinsic pathways are initiated by different mechanisms but the two
pathways join at the point where caspases 2,3, and 7 are activated.

deficient murine epithelial cell line would accumulate more chromate-specific genetic
damage and thus be more sensitive to chromate than a NEIL1 proficient murine epithelial
cell line. However, since the NEIL1 deficient cells were still capable of excising some
chromate-induced Sp lesions from duplex DNA, we thought that the sensitivity difference
between these two mammalian cell lines would not be as pronounced as had previously
been observed in Nei deficient versus Nei proficient E. coli.15 Instead, the NEIL1
deficient cell line was less sensitive to chromate than its wild type counterpart. The only
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difference between the two cell lines used in this study was the inactivation of a single
BER glycosylase, NEIL1, and yet we found striking cell cycle progression differences
between the two cell lines following exposure to chromate. The NEIL1 deficient cell line
also demonstrated apoptosis resistance. As apoptosis resistance is a hallmark of cancer,
this may provide evidence to explain why deletions in the 15q chromosome arm (the
location of the Neil1 gene) are observed in more than 70% of human small cell lung
carcinomas.16 This information taken together suggests that NEIL1, unlike other BER
glycosylases including OGG1, plays a more dynamic role in maintaining control of the
cell cycle engine than would be seen if this protein were solely involved in excising
oxidized nucleobase lesions.

3.2

Materials and Methods

3.2.1

Chromium Uptake Analysis

Chromate-treated cells that had

formed a complete monolayer were harvested as described previously using TrypsinEDTA and lyophylized prior to digestion. For each freeze-dried sample, 1 mL of trace
metal grade nitric acid (Fisher) was added and allowed to react for two hours. This was
followed by the addition of 200 uL of 30% hydrogen peroxide (J.T. Baker). Samples
were then allowed to digest for 48 hours uncovered in a ventilation hood. Being careful
not to disturb the salts which settled to the bottom of each tube, the liquid was transferred
to a second 15 mL conical tube and brought up to a volume of 7 mL with nanopure water.
Each sample was then analyzed for chromium content using an ICP-AES (IRIS Thermo
Jarrell Ash).

3.2.2

Cell Quantification and Plating

Neil1+/+, Neil1+/-, and Neil1-/-

epithelial cells were harvested using Trypsin-EDTA. Cells were placed in 15 mL conical
tubes and pelleted at 300 x g. Each sample was resuspended in 10 mL of complete media.
A 20 µL aliquot of each cell suspension was placed on a hemocytometer for counting.
Cell samples were then diluted to a final concentration of 10,000 cells/mL. Once diluted,
cells were distributed in 96-well plates (200 µL/well or 2,000 cells/well).
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3.2.3

Toxicity Assay

Plated cells were allowed to grow for 48 hours at

37o C and 5% CO2 before being treated with K2Cr2O7 (J.T. Baker). Chromate solutions
were made up as a 5X stock using filtered sterilized water. Media was removed from the
96-well plates. Each stock solution was diluted to the final 1X concentration using
complete media before being added to the 96-well plates. The final concentrations of
chromate used for the toxicity assay were 0, 1, 5, 10, 15, 20, 25, 30, 40, and 50 µM.

The

plates were maintained for 24 hours under the conditions listed above.
Chromate solutions were removed and each plate was then rinsed with 1X
phosphate buffered saline (PBS). CellTiter-Blue (Promega) was mixed with complete
media to form a 10% CellTiter-Blue solution. 200 µL of this solution was added to each
well in the 96-well plate. Plates were allowed to incubate in the CellTiter-Blue solution
for 22 hours at which time fluorescence at 585 nm (excitation at 555 nm and cut-off at
570 nm) was measured using the SpectraMax M2e Molecular Devices fluorescent plate
reader.

3.2.4

Cell Cycle Analysis

Neil1+/+, Neil1+/-, and Neil1-/- cells in the log

phase of growth were exposed to chromate (0, 10, 20, 30, 50 µM concentrations) for 24
hours in 75 cm2 flasks. Flasks were rinsed with 1X PBS and harvested using TrypsinEDTA. From this point forward, the cells were kept at 4oC unless otherwise noted. Cells
were transferred from flasks to 15 mL conical tubes and pelleted at 500 x g for 5 min.
The supernatant was discarded and the pellet was washed with 1 mL of 1X PBS. Cells
were pelleted at 500 x g for 10 min. The supernatant was discarded and the pellet was
resuspended in ice cold 70% ethanol. Each sample was mixed well before being stored at
-20o C overnight. Cells were pelleted at 1000 x g for 5 min. and the ethanol was
discarded. Samples were resuspended in 990 µL of hypotonic buffer (0.5% Triton X-100
and 100 µg/mL RNAse A (Sigma) prepared in 1X PBS) and incubated on ice for 30 min.
10 µL of a 500 µg/mL propidium iodide (Sigma) solution was then added and samples
were allowed to incubate on ice for 30-60 min. DNA content was analyzed by
fluorescence at 617 nm (excitation at 535 nm and cut-off at 565 nm) in a FACScan laser
flow cytometer (Becton Dickenson).
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3.2.5 BrdU TUNEL Assay

Neil1+/+ and Neil1-/- cells in the log phase of

growth were exposed to chromate (0, 10, 20, 30, 50 µM concentrations) for 24 hours.
Flasks were rinsed with 1X PBS and harvested using Trypsin-EDTA. From this point
forward, the cells were kept at 4o C unless otherwise noted. Cells were transferred from
flasks to 15 mL conical tubes and pelleted at 500 x g for 5 min. The supernatant was
discarded and the pellet was washed with 1 mL of 1X PBS. Cells were pelleted at 500 x g
for 10 min. The supernatant was discarded and the pellet was resuspended in ice cold
70% ethanol. Each sample was mixed well before being stored at -20o C overnight. Cells
were pelleted at 1000 x g for 5 min. and the ethanol was discarded. Pellets were
resuspended in 0.5 mL of wash buffer provided in the APO-BrdU TUNEL Assay Kit
(Invitrogen). Samples were stained with an Alexa Fluor 488 anti-BrdU antibody and
propidium iodide as directed in the APO-BrdU TUNEL Assay Kit. Each sample had a
final volume of ~600 µL. Three 200 µL aliquots of each sample were added to a 96-well
plate and fluorescence was measured on a SpectraMax M2e Molecular Devices
fluorescent plate reader at 519 nm (excitation at 495 nm and cut-off at 510 nm) for the
Alexa Fluor 488 stain and at 617 nm (excitation at 535 nm and cut-off at 565 nm) for the
propidium iodide stain.

3.2.6 PARP-1 Assay

Neil1+/+ and Neil1-/- cells were seeded at 1000

cells/ml in 96-well plates and allowed to incubate for 48 hours. Cells were exposed to
chromate (0, 10, 20, 30, 50 µM concentrations) or a known apoptosis inducing agent,
etoposide (50 µM concentration), for 24 hours. Cells were washed with 1X PBS before
cell extracts were obtained and labeled with anti-PAR antibody using the method outlined
in the HT Chemiluminescent PARP/Apoptosis Assay (Trevigen). PARP-1 activity in the
form of PAR addition to histone proteins was then monitored as chemiluminescence at all
wavelengths on a SpectraMax M2e Molecular Devices fluorescent plate reader.

3.2.7

Statistical Analysis Error bars in all of the graphs for chapters 3 and 4

represent the standard deviation in the average values shown. Figures 3.6 and 3.8 also
have statistical data provided. Statistical calculations were done using the Student’s two-
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tailed T-test assuming equal variance. The number of observations gathered for the
graphical representations is listed as “n” in the figure legends accompanying each graph.

3.3

Results

3.3.1

Chromate Toxicity Neil1+/+, Neil1+/-, and Neil1-/- epithelial cells were

exposed to Cr(VI) for 24 hours to observe their sensitivity to chromate. A toxicity curve
was generated based on the percentage of cells that were still alive as compared to an
untreated control sample following the 24 hour Cr(VI) exposure and a 22 hour incubation
period in the CellTiter-Blue solution. CellTiter-Blue is a solution of resazurin dye which
is taken up by and reduced to resorufin by live cells. Those cells that maintained an intact
membrane were able to take up and reduce the resazurin dye to resorufin. The
fluorescence of the resorufin was monitored for 24 hours at 585 nm to determine the
optimal length of time for exposure of the epithelial cells to this stain. A maximal level of
fluorescence was reached after 22 hours.
The epithelial cells were exposed to Cr(VI) concentrations ranging from 0 to 50
µM. The Neil1+/+ and Neil1+/- cell lines demonstrated similar responses to chromate
exposure with an LD50 occurring at a Cr(VI) concentration of approximately 40 µM
(Figure 3.4). In contrast, the Neil1-/- cell line showed significantly greater tolerance to
chromate than the Neil1+/+ and Neil1+/- cell lines at all Cr(VI) exposure levels except 1
and 5 µM (Figure 3.4). In a second trial, cells were dosed with chromate at
concentrations between 50 and 100 µM to determine the LD50 for the Neil1-/- cell line and
to determine at what point the two cell lines would again have equivalent survival
percentages. The LD50 for the Neil1-/- cell line was not reached until they had been
exposed to a chromate concentration of nearly 70 µM. Once the Neil1+/+ cells reached the
50 µM exposure level, the amount of error in the data increased dramatically
corresponding to a less than 50% cell survival rate. This same trend was observed for the
Neil1-/- cells except that the 50% cell survival rate was not reached until the 70 µM
exposure level. From that point forward, there is no longer any statistical difference in
the cell survival percentages between the two cell lines. The data from this additional
toxicity trial is presented in figure 3.5.
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Figure 3.4 – Toxicity curve for chromate exposure of the NEIL1 cell lines. The Neil1-/cell line shows reduced sensitivity to Cr(VI) as compared to the Neil1+/+ cell line. The
Neil1+/+ and Neil1+/- cell lines demonstrated similar responses to chromate exposure with
the LD50 occurring at a Cr(VI) concentration of approximately 40 µM. For each data
point reported, n = 8 observations.
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Figure 3.5 – Extended toxicity curve for chromate exposure of the NEIL1 cell lines. The
LD50 for the Neil1-/- cell line does not occur until a chromate concentration of nearly 70
µM is reached. The Neil1-/- cell line maintains a decreased sensitivity to chromate as
compared to the Neil1+/+ cell line until an 80 µM dosage is reached. From that point
forward, there is no statistical difference in the sensitivity between the two cell lines. For
each data point reported, n = 8 observations.

3.3.2

Chromium Uptake Analysis

NEIL1 deficient and proficient

epithelial cells were dosed with chromate and then analyzed for uptake. Harvested whole
cells were digested and diluted so they could be analyzed by ICP-AES. It was important
to monitor chromium uptake in each of the NEIL1 cell lines to ensure that one cell line
was not being exposed to higher intracellular chromium concentrations than the other.
Chromate is taken up by cells through non-selective anion channels that normally regulate
uptake of phosphate and sulphate.17 Cells that are actively growing will require a large
amount of phosphate and sulphate for construction of proteins and nucleotides.
Therefore, when chromate is present in the extracellular matrix, rapidly replicating cells
will also inadvertently take in large amounts of chromate along with the influx of
phosphate and sulphate. Our ICP-AES data revealed that chromate uptake was equivalent
between the NEIL1 cell lines at 5 and 50 µM extracellular exposure levels. However, at
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the intermediate exposure levels (10, 20, and 30 µM) there was a significant difference in
chromate uptake but it was not always the Neil1+/+ cell line taking up larger amounts of
chromate as we would have expected. The Neil1+/+ cell line took up larger amounts of
chromate than the Neil1-/- cell line at the 10 and 20 µM exposure levels but the Neil1-/- cell
line took up more chromate at the 30 µM level as shown in figure 3.6.
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Figure 3.6 – Chromium uptake was monitored on a pg of chromium/cell basis. A
statistically significant difference was observed for chromium uptake at 10, 20, and 30
µM chromate exposure levels (* = 95% CL, # = 99% CL). Neil1+/+ cells took up a
greater amount of chromium at the 10 and 20 µM exposure levels and Neil1-/- cells took
up a greater amount of chromium at the 30 µM level. All cell lines took up equivalent
amounts of chromium at the 5 and 50 µM exposure levels. For each data point reported, n
= 3 observations.

3.3.3

Cell Cycle Progression Following Chromate Exposure

Induction of DNA damage can lead to cell cycle arrest allowing cells to repair the
damage before progressing further along in the cell cycle. Chromate exposure induces
DNA lesion formation and therefore exposure to chromate should cause cells to pause in
the G0 or G2 arrest phases while the damage is assessed and/or repaired. Similar to the
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differences observed in sensitivity to chromate, Neil1+/+ and Neil1-/- cells also showed a
difference in their progression through the cell cycle following chromate exposure. At
chromate exposure concentrations between 10 and 30 µM, the Neil1-/- cell line displayed
elevated percentages of cells progressing into the S and G2/M phases of the cell cycle as
compared to an untreated sample. The Neil1+/+ cell line however, maintained similar
percentages of its cells in the various phases of the cell cycle whether they had been
exposed to chromate or not. The heterozygous NEIL1 cell line data fell between that of
the Neil1+/+ and Neil1-/- cell lines at each stage of the cell cycle analysis. Figure 3.7a
shows the data from the G0/G1 phase analysis, figure 3.7b shows the S phase data, and
figure 3.7c shows the G2/M phase data. Percentages of cells in each of the cell cycle
phases were quantified based on propidium iodide (PI) fluorescence. PI is a DNA
binding fluorescent stain. Cells were injected onto a FACScan laser flow cytometer and
as they passed by the detector relative fluorescence was detected. Cells with a single
copy of DNA (G0/G1 phase) gave half the fluorescence counts of cells with two copies
(G2/M phase). Cells that were actively synthesizing DNA (S phase) gave fluorescence
counts somewhere in between those of the G0/G1 and G2/M phase cells.
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Figure 3.7a – All three NEIL1 cell lines have a similar percentage of cells in the G0/G1
phase of the cell cycle under chromate free growth conditions and following exposure to a
50 µM chromate concentration (80-90%). The Neil1+/+ cell line maintains that same level
of ~90% of cells in the G0/G1 phase at all chromate exposure levels. The Neil1-/- cell line
maintains only ~60% of its cells in the G0/G1 phase following exposure to 10, 20, and 30
µM chromate concentrations.
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Figure 3.7b – All three NEIL1 cell lines have a similar percentage of cells in the S phase
of the cell cycle under chromate free growth conditions and following exposure to a 50
µM chromate concentration (5-14%). The Neil1+/+ cell line maintains that same level of
only 5% of cells in the S phase at all of the chromate exposure levels but the Neil1-/- cell
line maintains between 27-37% of its cells in the S phase following exposure to 10, 20,
and 30 µM chromate concentrations.
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Figure 3.7c – All three NEIL1 cell lines have a similar percentage of cells in the G2/M
phase of the cell cycle under chromate free growth conditions and following exposure to a
50 µM chromate concentration (6-8%). The Neil1+/+ cell line shows a reduced percentage
of cells in the G2/M phase (2%) following exposure to a 20 µM chromate concentration.
However, the Neil1-/- cell line spikes to having as much as 12-16% of its cells in the S
phase following exposure to 20 and 30 µM chromate concentrations.

3.3.4

Quantification of Free 3’-OH Ends

The presence of high numbers

of free 3'-hydroxyl ends in DNA can indicate that a cell is undergoing a large amount of
excision repair18 or that it has entered an apoptotic pathway which has lead to degradation
of genomic DNA.19 Terminal deoxynucleotidyl transferase (TdT) is an enzyme that will
add any deoxyribonucleotide to free 3'-hydroxyl ends.20 Using 5-bromo-2'-deoxyuridine
5'-phosphate (BrdUTP) – a deoxythymidine analog – and TdT, free 3'-hydroxyl groups in
genomic DNA can be efficiently labeled. These groups can then be detected by further
labeling the free 3'-hydroxl groups with an anti-BrdU antibody coated with an Alexa
Fluor 488 fluorescent tag. Epithelial cells from the NEIL1 proficient and deficient cell
lines were analyzed for the presence of free 3'-hydroxyl ends using the above described
transferase dUTP nick end labeling (TUNEL) technique. Cells were also labeled with
propidium idodide (PI, an intercalating fluorescent DNA stain) as a way to quantify total
DNA allowing us to compare the amount of free 3'-hydroxyl ends relative to total DNA
per sample. All of the values were reported as a change in fluorescence from that of
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untreated cell samples. A control cell sample provided in the APO-BrdU TUNEL assay
kit was also analyzed in a similar fashion. The control cells were an HL60 cell line
treated with camptothecin to induce apoptotic degradation of genomic DNA. At all
chromate concentrations investigated, the Neil1+/+ cell line showed an increase in the
number of free 3'-hydroxyl ends over untreated Neil1+/+ cell samples. There was no
statistical difference observed in the number of free 3’-hydroxyl ends generated in the
Neil1-/- cell samples for any of the chromate treatment concentrations versus those that
were untreated. The relative number of free 3'-hydroxyl ends in the Neil1+/+ cells
exposed to 30 and 50 µM chromate concentrations was statistically equivalent to the
relative number observed in the control, HL60 cells.
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Figure 3.8 – Graphical representation of the number of free 3'-hydroxyl ends in genomic
DNA of NEIL1 cell lines following exposure to chromate. Values are reported as antiBrd-UTP fluorescence counts (Alexa Fluor 488) per PI fluorescence count. All values
represent difference in relative fluorescence from untreated NEIL1 proficient or deficient
cell samples. The * symbol indicates a statistical difference at the 99.9% confidence
level. A positive apoptosis control sample of HL60 cells treated with camptothecin is
also shown. For each data point reported, n = 6-9 observations.

3.3.5 PARP-1 Activity

Poly (ADP-ribose) polymerase (PARP-1) is an

enzyme that is involved in nuclear protein modification. It catalyzes the transfer of poly
(ADP-ribose) at DNA strand breaks.21 When apoptosis is initiated however, PARP-1 is
cleaved from a 116 kDa to an 85 kDa protein by Yama/CPP32β [caspase 3].21 The
cleaved PARP-1 enzyme then mediates the translocation of apoptosis inducing factor
from the mitochondria to the nucleus.22 Uncleaved PARP-1 activity can be monitored by
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measuring poly (ADP-ribose) deposition onto an immobilized protein, in this case histone
proteins. Based on the data from our BrdUTP TUNEL assay we knew that the NEIL1
proficient cell line was accumulating a significantly higher level of free 3'-hydroxyl ends
than the NEIL1 deficient cell line. By monitoring PARP-1 activity in the two cell lines
we were able to determine if that elevated level of free 3'-hydroxyl ends could be
attributed DNA repair, as indicated by high levels of PARP-1 activity, or to apoptosis as
indicated by depressed levels of PARP-1 activity. Values were reported as mU of poly
(ADP-ribose) per µg of total protein. Total protein values for each cell sample were
determined by BCA protein analysis using a Bicinchoninic Acid protein assay kit
(Pierce). PARP-1 activity values represent a difference in activity from that of untreated
cell samples. The NEIL1 proficient cells demonstrated an elevated PARP-1 activity level
following exposure to a 10 µM chromate concentration but very low levels of activity
following exposure to 20, 30 and 50 µM chromate concentrations. The NEIL1 deficient
cells had an opposite trend. PARP-1 activity was reduced initially (10 µM chromate
exposure level) and then increased dramatically (20, 30, and 50 µM chromate exposure
levels). A positive apoptotic control was also used as a comparison for PARP-1 activity.
Both Neil1+/+ and Neil1-/- cells were exposed to a 50 µM concentration of etoposide a
well-documented apoptosis inducing agent.23 Both cell lines showed similar trends in
PARP-1 activity following treatment with etoposide as when they were treated with 20,
30, and 50 µM concentrations of chromate in that PARP-1 activity was greatly reduced in
the NEIL1 proficient cells relative to PARP-1 activity in the NEIL1 deficient cells.
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Figure 3.9 – PARP-1 activity measured as poly (ADP-ribose) deposition on immobilized
histones. Neil1+/+ cells had elevated levels of PARP-1 activity at the 10 µM chromate
exposure level relative to the Neil1-/- cells but this activity was truncated at all other
exposure levels and in the etoposide control sample. Neil1-/- cells showed an initial
decrease in PARP-1 activity but elevated levels of activity relative to the Neil1+/+ cells at
all other exposure levels and in the etoposide (C) treated samples. For each data point
reported, n = 3 observations.

3.4

Discussion

3.4.1

Replication Coupled Base Excision Repair

BER glycosylases were

once thought to all function in a similar, cell cycle independent manner. Further studies
of these repair enzymes have shown that there are actually two distinct groups of BER
glycosylases that carry out two slightly different forms of BER. The classical form of
BER is now referred to as single nucleotide base excision repair (SN-BER).24 The SNBER pathway utilizes apurinic/apyrimidinic endonuclease 1 (APE-1) to process a βelimination product or polynucleotide kinase (PNK) to process a βδ-elimination product
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formed by a BER glycosylase.25 DNA polymerase β will then insert a new base using the
complementary strand as a template and the gap in the phosphate backbone will be sealed
by DNA ligase IIIα.26 This type of BER occurs in DNA that is not being actively
replicated and as such, does not utilize replication associated DNA polymerases or
ligases. In fact, it has been reported that the BER glycosylases OGG1 and NTH1 are not
even functional in single stranded DNA or replication bubble structures.27 Therefore, it
was of no surprise that although OGG1 and NTH1 function to remove oxidized
nucleobase lesions (Table 1.3), their expression has been shown to be cell cycle
independent. NEIL1 however, belongs to a second group of BER glycosylases that are
cell cycle regulated and function as part of a modified BER pathway linked to DNA
replication.
The second form of BER that has been identified is now defined as long patch
base excision repair (LP-BER).28,29 This second BER pathway functions in a very similar
manner to SN-BER except that it is active only during DNA synthesis.24 Since LP-BER
is utilized during DNA synthesis, the accessory proteins involved in this repair pathway
are proteins that are also involved in replication of undamaged DNA. SN-BER requires
the use of DNA polymerase β as it contains intrinsic β-lyase activity that facilitates the
removal of the 5’-terminal region formed by β- or βδ-elimination prior to insertion of a
new base.26 This step is undertaken by flap endonuclease 1 (FEN1) in LP-BER30 so that
DNA polymerases δ and ε, which are already being employed for DNA replication, can
fill in the AP site with a new base and then continue their progress along the DNA
template being actively replicated.28,29 The gap in the phosphate backbone will be sealed
by DNA ligase I which is also part of the normal DNA replication machinery.31
A major difference between the two forms of BER is that SN-BER is carried out
by individual proteins in relatively discrete steps whereas, LP-BER is carried out within a
large protein complex in which repair and replication proteins may remain associated
throughout the entire replication process. A DNA sliding clamp protein directs the
assembly and functionality of the replication complex. Proliferating cell nuclear antigen
(PCNA) is one DNA sliding clamp of particular interest to our research as it has been
demonstrated that NEIL1 strongly associates with PCNA24 as do several other BER
glycosylases (MYH and UDG) that like NEIL1 are also cell cycle regulated.32 Once
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loaded onto the DNA by replication factor C (RFC), PCNA then recruits replication
proteins such as DNA helicases, topoisomerases, polymerases, and glycosylases to
assemble into a large replication complex, thus initiating DNA synthesis.33
DNA synthesis will come to a halt when a lesion is encountered in the template
strand. Chromate may cause a variety of bulky lesions such as oxidatively induced
protein-DNA crosslinks, and DNA-DNA crosslinks. These lesions will typically recruit
nucleotide excision repair (NER) before synthesis has been initiated as they will
extensively perturb the natural structure of B-form DNA acting as a beacon for repair
systems. If these bulky lesions are still present when DNA replication is initiated, the
replication complex will be unable to read through those points of damage.27 Those bulky
lesions would then have to be repaired before the replication complex could be
reassembled and proceed with DNA synthesis. Small oxidative base lesions however, can
easily go undetected in the genome prior to DNA replication as they do not greatly disturb
the native DNA structure.27 Therefore, it is very likely that a replication complex will
encounter un-repaired oxidative base lesions such as Sp and Gh in genomic DNA from
cells exposed to chromate. These lesions will cause the replication complex to stall long
enough to either repair the lesion, or since the lesions are small, to read through the point
of damage.
NEIL1, but not NEIL2, production is up-regulated during the S phase of the cell
cycle.34,35 NEIL1, but not NEIL2, has also been shown to be stimulated by PCNA24
indicating that NEIL1 should be the glycosylase of choice to repair chromate induced
oxidative lesions such as Sp and Gh that are encountered during DNA replication.
Whether or not NEIL1 is part of the PCNA mediated replication complex from the initial
point of assembly until the completion of DNA synthesis, or if it is only recruited when
an oxidative lesion is encountered is still unknown. It has been demonstrated though that
NEIL1 activity is stimulated by PCNA,24 the DNA replication helicase Werner syndrome
protein (WRN) that is associated with the PCNA complex,36,37 and by the Rad9-Rad1Hus1 (9-1-1 complex) another DNA sliding clamp protein that carries out functions
similar to those of PCNA.38 When an Sp or Gh lesion is encountered during replication,
NEIL1 would be required to excise the lesion while the replication complex was
temporarily stalled. If NEIL1 is not present to repair the lesion, PCNA has the ability to
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recruit DNA polymerase η (a damage tolerant polymerase)39 to simply insert any base
across from the Sp or Gh lesion so that DNA synthesis can continue through the
essentially non-disruptive damage point. It is beneficial for the PCNA complex to
facilitate insertion of a single base mutation rather than to break apart because the
replication fork can then collapse completely forming a double strand break. A double
strand break requires recombination for repair40 which can lead to the loss of critical
genetic information when the template for recombination includes incomplete nascent
DNA strands.
When an Sp or Gh lesion is encountered and NEIL1 is present, the replication
complex would temporarily stall and the replication fork would partially collapse forming
a “chicken foot” structure40 in which the DNA template strands just down stream of the
“chicken foot” would re-anneal.41 NEIL1 would then bind to and excise the Sp or Gh
lesion. PNK could then process the AP site, FEN1 could process the 5’-terminal region,
polymerase δ/ε could insert a new base, and DNA ligase I could seal the nick in the
phosphate backbone. A DNA helicase such as WRN would once again denature the DNA
down stream of the “chicken foot” and PCNA would reinitiate DNA synthesis.41

3.4.2 Implications of NEIL1 Deficient Epithelial Cell Data

Our initial

hypothesis concerning the NEIL1 deficient murine epithelial cells was that they would
show increased sensitivity to chromate relative to their wild type counterpart as was
observed in Nei deficient E. coli.15 However, this cell line actually showed reduced
sensitivity to chromate with respect to the NEIL1 proficient cell line. This led us to
believe that NEIL1 must play a more complex role in maintenance of cellular homeostasis
than a classical mammalian BER glycosylase and or a BER glycosylase in a prokaryotic
system. The recent work outlined above shows that NEIL1 does in fact play a different
role in BER than OGG1 or NEIL2 in that NEIL1 functions to repair oxidized nucleobase
lesions in actively replicating DNA whereas OGG1 and NEIL2 carry out this function in
non-replicating DNA. Since NEIL1 is tied to replication, it is also inherently linked to the
cell cycle. This proposal is supported by the findings that expression of NEIL1 is
stimulated during the S phase of the cell cycle.34,35
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Our data revealed that NEIL1 deficient cells not only display reduced sensitivity
to chromate but that they also show aberrant cell cycle affects following chromate
exposure. The DNA damage induced by chromate should cause a cell to pause and assess
damage before moving along in the cell cycle, or in other words it should enter a period of
cell cycle arrest. While we did not observe a large increase in the percentage of NEIL1
proficient cells stalling in the G0/G1 phases, we did see a decrease in the percentage of
NEIL1 deficient cells in the G0/G1 phases following exposure to chromate. That
decrease in cells in the G0/G1 phases correlated with an increase in the percentage of
NEIL1 deficient cells found in the S and G2/M phases following exposure to chromate.
This data suggests not only that chromate exposure does not hinder NEIL1 deficient cells
from progressing through the S phase, it appears to stimulate cell cycle progression. This
is occurring despite the fact that they would be accumulating significantly more oxidative
DNA lesions than NEIL1 proficient cells. Thus, NEIL1 must play an essential role in
oxidative DNA lesion detection, signaling the cell to postpone cell cycle progression
while the damage is assessed and repaired. This proposal is supported by the fact that
DNA replication complexes have the potential to read through small nucleobase lesions24
if they are not repaired immediately following the encounter of a nucleobase lesion by the
repair complex. By employing damage tolerant polymerase η that will simply insert any
base across from the small nucleobase lesion, the replication complex can continue its
processivity along the DNA template without risking replication fork collapse and double
strand break formation.39
NEIL1 deficient cells not only display altered cell cycle characteristics following
exposure to chromate, they also appear to be apoptosis resistant. When a large amount of
DNA damage accumulates in a cell, p53 should signal the cell to switch from a survival
pathway that would involve DNA repair, to an apoptotic pathway that will eventually end
with the orderly degradation of genomic DNA.8 The NEIL1 deficient cells, unlike the
NEIL1 proficient cells do not appear to receive that apoptotic signal following exposure
to levels of chromate that are ultimately toxic to the NEIL1 proficient cells. A large
number of oxidative nucleobase lesions induced by reduced chromate in the cell would go
undetected prior to DNA replication because lesions like Sp and Gh are relatively small,
non-disruptive structures. During synthesis, DNA is progressively scanned by the
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replication complex, so any lesions not repaired prior to replication will be encountered
and will then be repaired or expressed as a mutation in the newly synthesized DNA. It
would be the job of NEIL1 to repair any Sp or Gh lesions encountered during replication
by utilizing the LP-BER pathway. However, if NEIL1 is absent from the replication
complex, it is likely that a single base mutation would be inserted opposite the lesion by
polymerase η allowing the replication process to continue.
Reading through nucleobase lesions would allow a large number of mutations to
build up in the newly synthesized DNA. The actual repair of such lesions before they can
be expressed as mutations, must then act as a signaling method. If too much repair is
going on, a cell may receive signals that it is too badly damaged to salvage its DNA
successfully so p53 would direct the cell into an apoptotic pathway. Without NEIL1
present, cells damaged by chromate exposure would not receive such a signal and would
therefore continue to replicate as if nothing were amiss. Essentially, they would become
apoptosis resistant. All the while, mutations would begin to accumulate in the newly
synthesized DNA. Thus apoptosis resistance in the NEIL1 deficient cells would allow for
accumulation of mutations that could eventually render the cells independent of cell cycle
checkpoints or in other words a cancerous cell may be created. For this reason, apoptosis
resistance is often referred to as a hallmark of cancer.

3.5

Conclusions
NEIL1 deficient murine epithelial cells display an increased tolerance for

chromate. They also did not enter cell cycle arrest following exposure to chromate and
displayed characteristics of apoptosis resistance. Apoptosis resistance following
chromate exposure would allow the NEIL1 deficient cells to accumulate mutations that
can act as initiators for cancer. If these mutations accumulate in genes required for cell
cycle control, gene transcripts would be altered and the cancer promotion stage would be
reached. Studies have shown that deletions in the 15q chromosome arm – the location of
the NEIL1 gene - are observed in more than 70% of human small cell lung carcinomas.16
Lung cancers have been the major reported form of cancer caused by chromate
exposure.42-45 Therefore, people that carry mutations in their NEIL1 gene would stand a
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higher risk of developing cancer from chromate exposure than those with two fully
functional NEIL1 gene alleles. These conclusions are based on the assumption that the
NEIL1 deficient cells accumulate oxidized base lesions following chromate exposure
since they do not enter the apoptotic pathway even after they have been exposed to levels
of chromate that lead to more than 50% toxicity in NEIL1 proficient cells. Accumulation
of mutations in the NEIL1 deficient cell lines will be discussed in the Chapter 4.
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CHAPTER 4
Lesion and Mutation Accumulation in NEIL1 Cell Lines

4.1

Introduction
The formation of oxidative DNA lesions in a cellular system may act as an

initiator for mutation formation if the lesions are not repaired. Single oxidative
nucleobase lesions can be potent sources for mutations as they do not typically cause a
large disruption in the overall structure of B-form DNA1 and can be overlooked prior to
transcription or replication of DNA. For example, an 8-oxoG lesion maintains a planar
ring structure similar to that of the four natural DNA bases G,C, T, and A. The N7 group
is simply shifted from being a hydrogen bond acceptor to a hydrogen bond donor.
Because the N7 group is not directly involved with the Watson-Crick hydrogen bonding
between a normal guanine residue and a cytosine residue, an 8-oxoG lesion can still
stably pair with a cytosine residue (Figure 4.1a). During a round of replication, the 8oxoG lesion may be flipped into the syn conformation by DNA polymerases and will then
be paired with an adenine residue (Figure 4.1b) leading to the formation of a G:C → T:A
transversion mutation.2
While 8-oxoG has been shown to induce G:C → T:A transversion mutations,2,3
the hydantoin lesions, Sp and Gh/Ia, have been shown to cause those same transversion
mutations at frequencies at least one order of magnitude higher.4 In addition to G:C →
T:A transversion mutations, Sp and Gh/Ia have also been shown to induce G:C → C:G
transversion mutations4-6 and are >98% mutagenic whereas 8-oxoG is approximately 5%
mutagenic.4,6,7 The Sp and Gh/Ia lesions have a significantly altered structure relative to
that of the parent guanine residue or an 8-oxoG lesion (Figure 4.2) making it more
difficult for these lesions to form appropriate hydrogen bonding schemes that do not
perturb the overall DNA structure. Since these lesions would create a more substantial
alteration in the DNA structure, they should theoretically be easier for the SN-BER
pathway to detect and repair prior to DNA replication. Sp lesions however, are identified
and excised by the NEIL1 glycosylase.8 NEIL1 expression is up-regulated during the S
phase9,10 and has been shown to associate with replication complex proteins indicating
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that NEIL1 is involved in LP-BER rather than SN-BER.11-14 Therefore, Sp lesions,
despite their tendency to create a more dramatic kink in the DNA phosphate backbone
than an 8-oxoG lesion, would typically not be repaired until a cell entered S phase
increasing the odds that a point mutation could be generated opposite an Sp lesion.
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Since repair of Sp is tied to the process of replication, DNA polymerase δ/ε will
fill in the AP site once the lesion has been excised by NEIL1 and the termini have been
processed by PNK15 or FEN1.16 Lesions such as 8-oxoG, will be replaced by DNA
polymerase β following excision via the SN-BER pathway.17 Studies have been
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conducted with these different polymerases to determine their accuracy in inserting a
specific base when the template nucleotide is an unrepaired lesion. It was reported that
pol β (the non-replication associated DNA repair polymerase) favored insertion of the
correct, dCMP residue across from an 8-oxoG lesion whereas pol δ (the replication
associated DNA polymerase) favored insertion of dAMP.18 This study indicated that
DNA replication polymerases would be more prone to insertion of point mutations than
DNA repair polymerases suggesting that unrepaired lesions such as Sp, would be highly
mutagenic when encountered during replication.
NEIL1 deficient murine epithelial cells show reduced sensitivity to chromate and
cell cycle aberrations including apoptosis resistance. Without the NEIL1 glycosylase
present to excise Sp lesions formed by oxidation of guanine residues by high valent
chromium species, the NEIL1 deficient cell line should accumulate point mutations. The
level of DNA repair in these cells should be attenuated possibly masking the extent of the
damage which was shown to be extensive enough to initiate an apoptotic cascade in
NEIL1 proficient cells. Instead of entering an apoptotic pathway, the NEIL1 deficient
cells continued to grow and divide even following exposure to chromate concentrations
that were far more than 50% lethal for the NEIL1 proficient murine epithelial cell line.
We thus anticipated that we would see an accumulation of point mutations in correlation
with an accumulation of Sp lesions in the NEIL1 deficient cells. To begin, we analyzed
the cells for 8-oxoG levels following chromate exposure. We did not observe a
significant difference in the maximal level of accumulated 8-oxoG lesions as expected
since the mOGG1 glycosylase was functional in both cell lines. We also analyzed an
MCF-7 (human breast cancer cell line) for 8-oxoG accumulation following chromate
exposure. This was done as a way to compare the trends observed in our 8-oxoG data
with another mammalian cell line with functional Ogg1 and Neil1 genes. Accumulation
of point mutations was analyzed using an Hprt forward mutation assay.

4.2

Materials and Methods

4.2.1 MCF-7 Cell Line Growth Conditions

MCF-7 cells were purchased

from ATCC. Cells were grown in DMEM containing 4.5 g/L D-glucose, L-glutamine,
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and 110 mg/L sodium pyruvate (Gibco) which was supplemented with 10% fetal calf
serum (HyClone), 1% 100X antibiotic-antimycotic (Gibco), 0.1 mM non-essential amino
acids (Gibco), and 10 µg/mL insulin (Sigma, pH 8.2). Cells were maintained at 37o C
under an atmosphere of 5% CO2.
4.2.2

Cell Treatment

Neil1+/+ and Neil1-/- murine kidney epithelial cells as

well as MCF-7 cells were exposed to Cr(VI) for 4 hours. The concentrations used for the
murine epithelial cell lines were 0, 10, 15, 25, 50 µM in correlation with the toxicity curve
obtained for those cell lines. MCF-7 cells were exposed to Cr(VI) at levels of 0, 10, 25
and 50 µM and/or to 100 nM 17β-estradiol (Sigma, E2) levels either alone or in
conjunction with Cr(VI) exposure. E2 exposure time was 48 hours with Cr(VI) being
applied for the final 4 hours of the treatment period.

4.2.3

Genomic DNA Extraction Neil1+/+, Neil1-/- epithelial cells and MCF7

cells were washed with 1X PBS and harvested using Trypsin-EDTA as outlined
previously. Cell samples were pelleted at 300 x g and the supernatant was discarded.
Each 15 mL conical tube was placed on ice followed by the addition of 1 mL of 4o C
DNA extraction buffer (0.1 M Tris-HCl, 0.1 M NH4Cl, pH 8.0). Cell pellets were mixed
thoroughly but gently and were then sonicated for 5 min. in a Branson 3200 sonicating
water bath. Cell samples were pelleted at 2400 x g (4o C) for 5 min. and the supernatant
was discarded. Pellets were resuspended in 300 µL of DNA extraction buffer containing
33 U of RNAse T1 (Sigma) and 200 µg of RNAse A (Sigma) and incubated at 37o C for 1
hour. 300 µL of DNA extraction buffer containing 300 µg of Proteinase K (Invitrogen)
and 1% SDS was then added. The samples were mixed thoroughly but gently and
allowed to incubate for an additional 1 hour at 37o C. 750 µL of concentrated phenol (pH
7.9, Sigma) was then added and each sample was vigorously mixed before the organic
and aqueous phases were separated by centrifugation at 2400 x g for 5 min. The
supernatant was removed and placed into a fresh 1.5 mL tube, mixed vigorously with 250
µL of a 25:24:1 phenol : chloroform : isoamyl alcohol solution (pH 7.9, EMD), and
separated by centrifugation at 12000 x g for 5 min. Again the supernatant was removed
and placed into a fresh 1.5 mL tube, mixed vigorously with 250 µL of a 24:1 chloroform :
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isoamyl alcohol solution (Sigma), and separated by centrifugation at 12000 x g for 5 min.
The supernatant was mixed with 30 µL of 10 M ammonium acetate (pH 5.0) and 1 mL of
-20o C 100% ethanol in a fresh 1.5 mL tube. Samples were mixed and DNA was allowed
to precipitate at -20o C overnight before being pelleted at 12000 x g (4o C) for 15 min.
The 100% ethanol was discarded and pellets were washed with 1 mL of -20o C 70%
ethanol. DNA was pelleted at 12000 x g (4o C) for 10 min. The 70% ethanol was
discarded, residual liquid was dried and the pellet was resuspended in 100 µL of
deionized water. Absorbance at 260 nm (OD260) was obtained for each DNA sample in
order to determine the DNA content of each sample.

4.2.4 DNA Hydrolysis

DNA samples were denatured by heating to 95o C

for 5 min. followed by flash cooling on ice for 3 min. Within one minute of being placed
on ice, 0.1 U of phosphodiesterase II (Worthington Biochemicals) prepared in deionized
water was added to each DNA sample. Samples were allowed to incubate at 37o C for 45
min. Addition of phosphodiesterase II and incubation at 37o C for 45 min. was repeated.
0.5 U of phosphodiesterase I (Worthington Biochemicals) buffered in 10 mM Tris-HCl,
10 mM NH4Cl, 1.5 mM MgCl, pH 8.9 was added to each sample and they were allowed
to incubate for 45 min. at 37o C. Addition of phosphodiesterase I followed by incubation
at 37o C for 45 min. was repeated. 5 U of calf intestinal phosphatase (Promega) buffered
in 50 mM Tris-HCl, 1 mM MgCl2, 0.1 mM ZnCl2, 1 mM spermidine, pH 9.3 was added
to each sample and they were allowed to incubate for 45 min. at 37o C. Addition of calf
intestinal phosphatase followed by incubation at 37o C for 45 min. was repeated. Samples
were cleaned up in YM-30 centrifugal filters (Microcon) by centrifugation at 2500 x g for
25 min. Samples were stored at -80o C until analysis.

4.2.5

8-oxoG Quantification

8-oxoG lesions were quantified and reported

as values relative to the amount of guanine present in each hydrolyzed DNA sample.
Hydrolyzed DNA samples were analyzed using an Agilent 1200 series HPLC coupled
with diode array detection for guanine quantification. Samples were separated using an
Agilent C18 4.6 mm x 100 mm column, with an isocratic mobile phase of 100 mM
ammonium acetate (pH 5.2) and 4% methanol at a flow rate of 1 mL/min. A calibration
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curve for guanine was generated from standards of dG ranging from 125 ng to 2500 ng.
The dG content of the hydrolyzed DNA samples was calculated by comparing dG peak
areas from 25 µL aliquots of hydrolyzed samples to the calibration curve. Separated
DNA was then further analyzed using an ESA CoulArray electrochemical detector.
Hydrolyzed DNA was subjected to four different voltages (50, 100, 150, 300 V) as it
passed across a model 6210 ESA electrical cell. 8-oxoG was oxidized in the 300 V
channel. A calibration curve for 8-oxoG was generated from standards of 8-oxoG ranging
from 25 pg to 625 pg. The 8-oxoG content of the hydrolyzed DNA samples was
calculated by comparing 8-oxoG peak areas from 25 µL aliquots of hydrolyzed samples to
the calibration curve.

4.2.6

Hprt Mutation Analysis

Resistance to 6-thioguanine (Sigma, 6-TG)

was assessed in both the Neil1+/+ and Neil1-/- cell lines using a fluorescence 96-well plate
assay. Cells were seeded in 96-well plates at a density of 1 x 104 cells/mL and allowed to
recover for 48 hours before being treated with 6-TG. Media was removed from the 96well plates and 6-TG solutions were added with the final concentrations of 6-TG being 0,
5, 10, 20, 30, 40, 50, 60, 70 and 80 µg/mL. Plates were allowed to incubate for 24 hours.
6-TG solutions were removed and each plate was then rinsed with 1X PBS. CellTiterBlue (Promega) was mixed with complete media to form a 10% CellTiter-Blue solution.
200 µl of this solution was added to each well in the 96-well plates. Plates were allowed
to incubate in the CellTiter-Blue solution for 22 hours at which time fluorescence at 585
nm (excitation at 555 nm and cut-off at 570 nm) was measured using a SpectraMax M2e
Molecular Devices fluorescent plate reader.
1 x 106 of cells from each cell line were seeded in 75 cm2 flasks and allowed to
recover for 24 hours. Cells were dosed with chromate for 24 hours (0, 5, 10, 20, 30 and
50 µM). Flasks were then washed with 1X PBS, refreshed with complete chromate-free
media and allowed to recover for 5 days. 1 x 106 cells from each cell line and treatment
level were seeded in 25 cm2 flaks. Complete media was supplemented with 20 µg/mL 6TG. Media, supplemented with 6-TG, was refreshed every 3-4 days. Cells were allowed
to incubate for 7 days or until colonies had formed. Media was then aspirated and cells
were incubated in a 2% methylene blue solution (100 mg methylene blue (Sigma)
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prepared in 50 mL of 50% ethanol) for five minutes. The methylene blue solution was
rinsed with deionized water and colonies were counted. Following recovery from
chromate treatment, Neil1+/+ and Neil1-/- cells were also seeded in 60 mm dishes at a
density of 400 cells/plate to monitor plating efficiencies. These cells were also allowed to
incubate for 7 days or until colonies had formed at which time they were stained with 2%
methylene blue and counted.

4.3

Results

4.3.1
+/+

Neil1

8-oxoG Quantification

Hydrolyzed DNA samples from both the

-/-

and the Neil1 cell lines were analyzed by diode array for guanine content

(Figures 4.3 and 4.4) and electrochemical detection for 8-oxoG content (Figure 4.5)
following exposure to chromate for 4 hours. Guanine and 8-oxoG content were
quantified by measuring peak area and comparing those values to a standard curve. New
guanine and 8-oxoG standards were analyzed prior to each analysis of the hydrolyzed
DNA if all samples could not be run in a single session.
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*DAD1 A, Sig=254,4 Ref=360,100 (LL8-OXOG 2007-08-02 09-25-28\006-0601.D)
*DAD1 A, Sig=254,4 Ref=360,100 (LL8-OXOG 2007-08-02 09-25-28\003-0301.D)
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Figure 4.3 – HPLC traces from a guanine standard (upper trace) and a digested DNA
sample (lower trace). Guanine eluted at approximately 8.5 min. in both samples. All four
DNA bases were visible in the digested DNA sample trace indicating that the DNA
hydrolysis was effective.

Figure 4.4 – Guanine was identified by its characteristic ultraviolet absorbance spectrum.
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Figure 4.5 – 8-oxoG elutes at 10 min. in channel 4. 8-oxoG is oxidized only in channel 4
of the electric cell at 300 V.

Both cell lines showed an initial increase in the number of 8-oxoG lesions present relative
to the total number of guanine residues in each sample as compared to levels of 8-oxoG
observed in the control samples. This increase was seen in the Neil1+/+ cell line only
between the untreated samples and the samples dosed with 10 µM chromate. The levels
of 8-oxoG in NEIL1 proficient cells dropped back to a level equivalent with that seen in
the untreated samples following exposure to 15, 25, and 50 µM chromate concentrations.
The increase in the relative level of 8-oxoG lesions present in the Neil1-1- cell line
increased in a dose dependent fashion over the untreated sample values following
exposure to both 10 and 15 µM chromate concentrations. After exposure to a 25 µM
chromate solution, the 8-oxoG levels in the NEIL1 deficient cell line fell from the level
seen in the samples dosed with 15 µM chromate. 8-oxoG levels in the NEIL1 deficient
cell line also returned to a level equivalent to that observed in the untreated samples but
only after being exposed to a 50 µM chromate solution. There was no significant
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difference observed in the maximum level of accumulated 8-oxoG lesions between the
two epithelial cell lines. This data is presented in figure 4.6.
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Figure 4.6 – 8-oxoG lesions relative to the total number of guanine residues present in
hydrolyzed DNA samples from NEIL1 epithelial cell lines exposed to chromate for 4
hours. Both cell lines show an initial, dose dependent increase in the level of 8-oxoG
lesions present but that increase is followed by a decrease back to levels equivalent to
those observed in the untreated samples. For each data point reported, n = 3-5
observations.

Hydrolyzed DNA from MCF-7 cells dosed with chromate and/or E2 were also
analyzed by electrochemical detection. E2 is a female hormone that has been shown to
induce ROS production in cells and to cause breast cancer development.19,20 The MCF-7
DNA samples demonstrated a similar trend in 8-oxoG levels relative to total guanine
residues as was seen in the NEIL1 DNA samples. Following exposure to chromate alone,
8-oxoG levels in the MCF-7 cells increased initially (10 µM chromate dose) relative to
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the level seen in untreated samples. The 8-oxoG levels then decreased following
exposure to 25 and 50 µM chromate concentrations. Samples dosed with E2 alone
developed higher 8-oxoG levels than untreated samples. The levels following E2
exposure were equivalent to those observed in samples dosed with 25 and 50 µM
chromate alone. Treating MCF-7 cells with both chromate and E2 caused a steep drop off
in the level of 8-oxoG lesions present. 8-oxoG levels in samples dosed with 100 nM E2
and 15 µM chromate fell below the level of 8-oxoG lesions observed in untreated
samples. This data is shown in figure 4.7.
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Figure 4.7 – 8-oxoG lesions relative to the total number of guanine residues present in
hydrolyzed DNA samples from MCF-7 cells exposed to chromate for 4 hours and/or E2
for 48 hours. 8-oxoG levels increase relative to those seen in untreated samples following
exposure to a 10 µM chromate solution and after exposure to E2 alone. The levels of 8oxoG drop off dramatically following exposure to both chromate and E2 to levels lower
than that observed in the untreated samples. For each data point reported, n = 3-4
observations.
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4.3.2

Hprt Mutation Assay

Chromate treated cells from both the

Neil1+/+ and Neil1-/- cell lines were allowed to recover for 5 days in chromate-free
complete media before being seeded in 60 mm dishes at a density of 400 cells per dish to
assess plating efficiency. These cells were maintained in 6-TG-free media for 6 days at
which time colonies had formed. Colonies were then stained and counted. The untreated
cells from both the NEIL1 proficient and deficient cell lines formed equivalent numbers
of colonies after 6 days (Figure 4.8a). This was followed by a slight increase in cell
colony formation in both cell lines for cells exposed to 5 µM chromate. The Neil1+/+
dishes then showed a steady decrease in the number of colonies forming in conjunction
with chromate treatment concentrations of 10, 20, 30, and 50 µM. The Neil1-/- cell dishes
showed a slight decrease in colony formation at the 10 µM treatment level but then a
significant increase in colony formation at the 20 and 30 µM treatment levels. Colony
numbers fell back to the level observed in the untreated Neil1-/- dishes for cells treated
with 50 µM chromate. The same trends presented themselves when colony formation was
represented as a percentage of colonies in the control dishes (Figure 4.8b). Error in this
data was quite high because of the small number of colonies that formed in the dishes.
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Figure 4.8 – A similar number of colonies were counted in dishes containing untreated
Neil1+/+ and Neil1-/- cells. Cell growth was initially stimulated in both cell lines at the 5
µM chromate treatment level but then steadily declined for the Neil1+/+ cell line. Growth
continued to be stimulated by chromate exposure in the Neil1-/- cell line through the 30
µM chromate treatment level with colony formation dropping back to near control levels
following exposure to 50 µM chromate.

Mutation accumulation in the Hprt gene was assessed by seeding 1 x 106 cells in
25 cm2 culture flasks for both the Neil1+/+ and Neil1-/- cell lines following chromate
treatment and a 5 day recovery period. These cells were then maintained for 7 days in
media supplemented with 20 µg/ml 6-TG. In order for cells to grow and form colonies in
the presence of 6-TG, they must have first developed mutations in the Hprt gene. No
quantitative data was able to be obtained for comparisons between the Neil1+/+ and
Neil1-/- cell lines in this assay but some qualitative observations could be made. No
colonies formed in any of the Neil1+/+ culture flasks (Figure 4.9a) indicating that 6-TG
was toxic to these cells even following exposure to chromate. Colonies did form in flasks
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seeded with Neil1-/- cells exposed to 0, 5, 10 and 20 µM chromate (Figure 4.9a-B).
Colonies did not form in flasks seeded with Neil1-/- cells dosed with 30 and 50 µM
chromate, instead the cells grew to confluence (Figure 4.9b). Since colonies did form in
the Neil1-/- culture flasks dosed with 0, 5, 10, and 20 µM chromate, a quantitative trend in
colony number could be presented graphically (Figure 4.10). Colony formation initially
increased for flasks at the 5 µM chromate exposure level but then fell back to control
values by the 20 µM chromate exposure level.

Figure 4.9a – Differences in colony formation between (A) Neil1+/+ and (B) Neil1-/- cells.
Both flasks were seeded with 1 x 106 cells that had not been exposed to chromate and
were then grown in media supplemented with 20 µg/ml 6-TG for 7 days. Neil1+/+ culture
flasks looked identical for all chromate exposure levels.
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Figure 4.9b – Differences in colony formation between (A) Neil1-/- cells dosed with 30
µM chromate and (B) Neil1-/- untreated cells. Both flasks were seeded with 1 x 106 cells
and grown in media supplemented with 20 µg/ml 6-TG for 7 days. Neil1-/- culture flasks
for the 0, 5, 10, and 20 µM chromate exposure levels looked similar to (B) but with
varying numbers of colonies present. Neil1-/- culture flasks for the 30 and 50 µM
chromate exposure levels looked identical to (A).
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Figure 4.10 – Colony formation trends for the Neil1-/- cell line maintained in media
supplemented with 20 µg/ml 6-TG for 7 days following treatment with chromate. Colony
numbers increase over control levels at the 5 µM chromate exposure level and then began
to fall back to control values by the 20 µM chromate exposure level.

4.4

Discussion

4.4.1

Formation and Detection of Further Oxidized Lesions In studies

conducted in E. coli, Sp lesions, but not 8-oxoG lesion, were observed to accumulate in
an Nei deficient E. coli strain.21 Based on that information, we hypothesized that a
NEIL1 deficient mammalian cell line would also accumulate large amounts of Sp
following exposure to chromate. Mammalian cells however, unlike E. coli. used in
previous studies, have three variants of the Nei repair protein, NEIL1, NEIL2, and
NEIL3.9,10,22 A separate study has demonstrated that NEIL2 has the ability to excise Sp
lesions in vitro as it was capable of cleaving Sp from single-stranded oligonucleotides.8
Therefore, while we anticipated that NEIL1 deficient murine epithelial cells would
accumulate Sp lesions, we also hypothesized that the accumulation may not occur at such
pronounced levels as was seen in Nei deficient E. coli. as the NEIL1 deficient cell line
maintains two functional Neil2 alleles.
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Sp lesions from E. coli DNA were quantified using a Waters 2790 HPLC coupled
to a Micromass LCT mass spectrometer with electrospray ionization.21 Unfortunately this
analysis method was not effective for the NEIL1 epithelial cell lines. Several problems
arose that prevented Sp quantification in these cell lines. The Waters mass spectrometer
system was a core instrument and as such carried a wide variety of low level
contaminants from polymers and buffers that had been run through the system. In order
to detect Sp in DNA samples, a level of sensitivity in the 1 pmol range had to be reached.
These low levels of Sp were essentially undetectable when contaminants such as high
levels of salts were ionized along with the DNA samples. Another problem with this
detection set-up was that a C18 reverse phase Microsorb 2.1 mm x 250 mm column was
used for separation of the DNA bases prior to ionization in the mass spectrometer. Sp is a
highly polar molecule and therefore does not interact strongly with a C18 matrix causing
it to elute rapidly, often so quickly that it emerged in the buffer front. Another hurdle was
obtaining large enough quantities of DNA from the epithelial cells for analysis. The
ability to grow vast amounts of E. coli. in just 24 hours makes it much easier to obtain
large quantities of DNA than when one is working with mammalian cells that may take 5
days to reach confluence. Low amounts of DNA combined with the inherent problems
with the mass spectrometer and the C18 column, prevented detection of Sp above
background using the method previously employed for Sp detection.
Methods are being developed using a dedicated Agilent LC/MSD Trap XCT mass
spectrometer coupled to an Agilent 1200 series HPLC to improve detection limits for Sp
and Gh lesions in genomic DNA and decreased interference from contaminants within the
system. The new methods being developed also use a Thermo Hypercarb 4.6 mm x 150
mm column for HPLC separation prior to analysis by ion trap mass spectrometry.
Retention times for Sp on the C18 reverse phase Microsorb column were between 5 and 7
minutes but on the Thermo Hypercarb column, Sp does not elute until 15 minutes for the
(-) isomer and 25 minutes for the (+) isomer (Figure 4.11a). A mobile phase gradient was
employed over 21 minutes from 99% mobile phase A (deionized water + 0.1% acetic
acid) and 1% mobile phase B (methanol) to 100% mobile phase B at a constant flow rate
of 0.9 ml/min. We are also now able to conduct MS/MS analysis of the 300 molecular

85

weight ion associated with the Sp nucleoside in order to monitor the 184 molecular
weight ion associated with the Sp free base (Figure 4.11b and 4.12).
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Figure 4.11a – Sp isomers from a single stranded oligonucleotide oxidized with Cr(V)Salen. These isomers were separated and detected on an Agilent LC/MSD Trap XCT
mass spectrometer. The Sp (+) appears to be the dominant species formed in single
stranded oligonucleotides and in MCF-7 DNA digests.
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Figure 4.11b – The Sp isomer peaks from (a) both represent ions with a mass to charge
ratio of 184. This 184 mass peak generated by free Sp base was obtained by splitting the
300 mass peak that is generated as the Sp nucleoside moves into the ion trap.

Some initial analysis have shown that Sp is present at levels above background in
hydrolyzed DNA samples from MCF-7 cells exposed to chromate and E2. Hydrolyzed
DNA samples from MCF-7 cells were used to look for Sp in our initial ion trap mass
spectrometry trials for several reasons. First, these cells grow rapidly making it much
easier to obtain large amounts of genomic DNA than from the much slower growing
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NEIL1 epithelial cell lines. Secondly, a recent report looking at 8-oxoG metabolism in
MCF-7 cells showed that further oxidized lesions may have been present in MCF-7 cells
dosed with E2.23 Following exposure to E2, hydrolyzed DNA samples from MCF-7 cells
were analyzed using HPLC- accelerator mass spectrometry (AMS) and five peaks eluted
that could not be attributed to 8-oxoG or any of the four natural DNA bases23 indicating
that further oxidized lesions such as Sp may have been forming. Of the Sp detected in our
MCF-7 digests, the Sp(+) isomer appears to be the dominant species present. The Sp(+)
isomer also appears to be the dominant species formed in oligonucleotides containing an
8-oxoG lesion that have been oxidized with Cr(V)-Salen or with Na2IrCl6 (Figure 4.11a).
This new system for Sp analysis has yet to be applied to DNA digests from the NEIL1
cell lines but we are hopeful that this system will be effective for detecting Sp at the 1
pmol level.
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Figure 4.12 – Mass profile of the Sp nucleoside and the free base.

4.4.2

Implications of the Hprt Mutation Assay The basis for detecting

mutations in an Hprt mutation assay is resistance to the mutagen 6-TG. Under normal
conditions, a cell that is exposed to 6-TG will produce functional copies of hypoxanthine-

87

guanine phosphoribosyl transferase (HPRT) which will metabolize 6-TG into a highly
toxic mutagen.24 As the number of mutations that a cell develops in the Hprt gene
increases, so do the chances that a non-functional HPRT protein will be produced and
resistance to 6-TG will ensue as 6-TG will not be metabolized. For this study, our
hypothesis was that the Neil1-/- murine epithelial cells should accumulate mutations
following exposure to chromate as compared to the Neil1+/+ cell line because they have
an attenuated ability to repair the oxidative lesion Sp. Therefore, we expected that Neil1/-

cells exposed to chromate and then allowed to undergo several rounds of replication

would show an increased resistance to 6-TG as compared to their wild type counterpart.
In order to evaluate whether or not differences in colony formation for the Neil1+/+
versus the Neil1-/- cell lines were caused solely by exposure to 6-TG, cells from both lines
and at all chromate treatment levels needed to be plated in 6-TG-free media to
simultaneously assess plating efficiencies. Figure 4.8a-b shows that untreated Neil1+/+
and Neil1-/- cells both form similar numbers of colonies when seeded at a density of 400
cells per 60 mm culture dish and allowed to incubate in 6-TG-free media for 6 days.
However, exposure to chromate appears to stimulate the growth of the Neil1-/- cells
whereas it attenuates growth in the Neil1+/+ cell line. A second control used in this
experiment was the determination of 6-TG toxicity in both the NEIL1 cell lines. Using
the same CellTiter-Blue fluorescence assay described in chapter 3, NEIL1 cells were
dosed with 6-TG for 24 hours to determine a 50% toxicity level. Both cell lines reached a
level of approximately 50% toxicity at a treatment level of 20 µg/ml 6-TG. One
drawback to this toxicity assay however, was that it only assessed toxicity on a very short
time scale. It did not show whether or not cells would be able to actively replicate
following treatment with 6-TG but it provided a good starting point for this particular
assay.
Figure 4.9a showed that untreated Neil1+/+ cells were unable to survive over a
longer time frame (7 days) when exposed to 6-TG at a level of 20 µg/ml. The untreated
Neil1-/- cells however, appeared to thrive despite the addition of 6-TG to the media and
despite the fact that they had a nearly identical plating efficiency as the Neil1+/+ cells.
This indicated that the Neil1-/- cells may accumulate mutations endogenously even in the
absence chromate treatment. There are a large number of oxidants that routinely bombard
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DNA but the resulting low level of oxidative lesions would be excised and repaired in a
normal cellular system. The Neil1-/- cell line does not have a complete base excision
repair system since the Neil1 gene has been interrupted so it may accumulate some
oxidative lesions even when not oxidatively stressed with chromate.
Figure 4.10 showed that colony formation actually increased over control levels
for the Neil1-/- cells grown in 6-TG following exposure to increasing concentrations of
chromate. It is difficult to say that this increased growth is solely due to increased 6-TG
resistance because exposure to chromate actually stimulated cell growth as shown in
figure 4.8a-b. Some of the increase in colony formation may be attributed to 6-TG
though, based on the change in growth patterns observed for the 30 and 50 µM chromate
treatment levels as shown in figure 4.9b. The Neil1-/- culture flasks for the 0-20 µM
chromate treatment levels formed colonies in the presence of 6-TG as is typically
observed when cells are plated at very low densities in mutagen-free media. Those flasks
for the 30 and 50 µM chromate treatment levels showed cells growing to confluence in
the presence of 6-TG as is typically observed when cells are plated at much higher
densities in mutagen-free media. This qualitative observation makes it appear as though
the Neil1-/- cells dosed with the highest chromate concentrations are growing significantly
better than those dosed with lower chromate concentrations. Plating efficiencies show
that growth fell back to control levels after a 50 µM chromate treatment but the 6-TG
assay indicated that growth in flasks for the 50 µM chromate treatment level were still
growing better than those at the 20 µM or lower chromate treatment levels.
The striking differences in 6-TG toxicity between the two NEIL1 cell lines will
make it difficult to use a colony formation approach to compare mutation accumulation in
the two cell lines. This assay could be repeated using lower 6-TG concentrations in order
to allow colonies to form in the NEIL1 proficient flasks, but this approach will likely lead
to overgrowth of the Neil1-/- cells. Another approach would be to treat the two cell lines
with different 6-TG concentrations. However, the best way to move forward from this
point would most likely be to sequence the Hprt gene in both cell lines and look for
changes in mutation levels following exposure to chromate and selective growth in the
presence of 6-TG. We would expect to see a high number of mutations at guanine
residues following exposure to chromate. This approach would also determine whether or
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not Neil1-/- cells accumulate mutations even under conditions that should not oxidatively
stress the cells. However, we would anticipate that these mutations would not be
concentrated specifically at guanine residues.

4.5

Conclusions
The Neil1-/- cell line has demonstrated a vastly different response to chromate than

its wild type counterpart. Chromate is less toxic to the Neil1-/- cells despite the fact that
they appear to retain some ability to excise Sp (potentially via a NEIL2 pathway). In
addition, chromate also stimulates growth in the NEIL1 deficient cell line and can even
induce apoptosis resistance. Levels of 8-oxoG are not significantly higher in the Neil1-/cell line following chromate treatment so it stands to reason that the affects that we have
observed may be linked to further oxidized products. More specifically, further oxidized
base lesions since the only part of the genome that has been altered in the Neil1-/- cells is a
single gene that codes for a BER glycosylase specifically designed for removal of
oxidized nucleobase lesions. Mutation accumulation should also be assessed in a more
specific manner. Sequencing the Hprt gene to quantify mutations at guanines would
provide the most conclusive data on this point. In the big picture, developing a better
understanding of the role that NEIL1 plays in protecting a cell from oxidative damage
induced by chromate exposure has the potential to play an important part in preventing
cancer formation in humans. We could use our knowledge about NEIL1 to develop
biomarkers to identify people at high risk and advise them against working in a field
where chromate exposure is unavoidable. A better understanding of how chromate can
induce cancer will also be important as this information would aid in the search for better
ways to treat those already affected by chromate induced lung carcinomas.
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